<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PeerJ</journal-id><journal-id journal-id-type="iso-abbrev">PeerJ</journal-id><journal-id journal-id-type="publisher-id">peerj</journal-id><journal-id journal-id-type="pmc">peerj</journal-id><journal-title-group><journal-title>PeerJ</journal-title></journal-title-group><issn pub-type="epub">2167-8359</issn><publisher><publisher-name>PeerJ Inc.</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4918724</article-id><article-id pub-id-type="publisher-id">2119</article-id><article-id pub-id-type="doi">10.7717/peerj.2119</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Oncology</subject></subj-group></article-categories><title-group><article-title>Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis</article-title></title-group><contrib-group><contrib id="author-1" contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Ab Mutalib</surname><given-names>Nurul-Syakima</given-names></name><email>syakima@ppukm.ukm.edu.my</email><xref ref-type="aff" rid="aff-1">1</xref></contrib><contrib id="author-2" contrib-type="author" equal-contrib="yes"><name><surname>Othman</surname><given-names>Sri Noraima</given-names></name><xref ref-type="aff" rid="aff-1">1</xref></contrib><contrib id="author-3" contrib-type="author"><name><surname>Mohamad Yusof</surname><given-names>Azliana</given-names></name><xref ref-type="aff" rid="aff-1">1</xref></contrib><contrib id="author-4" contrib-type="author"><name><surname>Abdullah Suhaimi</surname><given-names>Shahrun Niza</given-names></name><xref ref-type="aff" rid="aff-2">2</xref></contrib><contrib id="author-5" contrib-type="author"><name><surname>Muhammad</surname><given-names>Rohaizak</given-names></name><xref ref-type="aff" rid="aff-2">2</xref></contrib><contrib id="author-6" contrib-type="author"><name><surname>Jamal</surname><given-names>Rahman</given-names></name><xref ref-type="aff" rid="aff-1">1</xref></contrib><aff id="aff-1"><label>1</label><institution>UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia</institution>, <addr-line>Cheras</addr-line>, <addr-line>Kuala Lumpur</addr-line>, <country>Malaysia</country></aff><aff id="aff-2"><label>2</label><institution>Department of Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia</institution>, <addr-line>Cheras</addr-line>, <addr-line>Kuala Lumpur</addr-line>, <country> Malaysia</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Zhao</surname><given-names>Min</given-names></name></contrib></contrib-group><pub-date pub-type="epub" date-type="pub" iso-8601-date="2016-06-15"><day>15</day><month>6</month><year iso-8601-date="2016">2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>4</volume><elocation-id>e2119</elocation-id><history><date date-type="received" iso-8601-date="2015-11-25"><day>25</day><month>11</month><year iso-8601-date="2015">2015</year></date><date date-type="accepted" iso-8601-date="2016-05-18"><day>18</day><month>5</month><year iso-8601-date="2016">2016</year></date></history><permissions><copyright-statement>&#x000a9;2016 Ab Mutalib et al.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Ab Mutalib et al.</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license></permissions><self-uri xlink:href="https://peerj.com/articles/2119"/><abstract><p><bold>Background</bold>. Papillary thyroid carcinoma (PTC) is the commonest thyroid malignancy originating from the follicle cells in the thyroid. Despite a good overall prognosis, certain high-risk cases as in those with lymph node metastasis (LNM) have progressive disease and poorer prognosis. MicroRNAs are a class of non-protein-coding, 19&#x02013;24 nucleotides single-stranded RNAs which regulate gene expression and these molecules have been shown to play a role in LNM. The integrated analysis of miRNAs and gene expression profiles together with transcription factors (TFs) has been shown to improve the identification of functional miRNA-target gene-TF relationships, providing a more complete view of molecular events underlying metastasis process.</p><p><bold>Objectives</bold>. We reanalyzed The Cancer Genome Atlas (TCGA) datasets on PTC to identify differentially expressed miRNAs/genes in PTC patients with LNM-positive (LNM-P) versus lymph node negative (LNN) PTC patients and to investigate the miRNA-gene-TF regulatory circuit that regulate LNM in PTC.</p><p><bold>Results</bold>. PTC patients with LNM (PTC LNM-P) have a significantly shorter disease-free survival rate compared to PTC patients without LNM (PTC LNN) (Log-rank Mantel Cox test, <italic>p</italic> = 0.0049). We identified 181 significantly differentially expressed miRNAs in PTC LNM-P versus PTC LNN; 110 were upregulated and 71 were downregulated. The five topmost deregulated miRNAs were hsa-miR-146b, hsa-miR-375, hsa-miR-31, hsa-miR-7-2 and hsa-miR-204. In addition, 395 miRNAs were differentially expressed between PTC LNM-P and normal thyroid while 400 miRNAs were differentially expressed between PTC LNN and normal thyroid. We found four significant enrichment pathways potentially involved in metastasis to the lymph nodes, namely oxidative phosphorylation (OxPhos), cell adhesion molecules (CAMs), leukocyte transendothelial migration and cytokine&#x02013;cytokine receptor interaction. OxPhos was the most significantly perturbed pathway (<italic>p</italic> = 4.70E&#x02212;06) involving downregulation of 90 OxPhos-related genes. Significant interaction of hsa-miR-301b with HLF, HIF and REL/NFkB transcription factors were identified exclusively in PTC LNM-P versus PTC LNN.</p><p><bold>Conclusion</bold>. We found evidence of five miRNAs differentially expressed in PTC LNM-P. Alteration in OxPhos pathway could be the central event in metastasis to the lymph node in PTC. We postulate that hsa-miR-301b might be involved in regulating LNM in PTC via interactions with HLF, HIF and REL/NFkB. To the best of our knowledge, the roles of these TFs have been studied in PTC but the precise role of this miRNA with these TFs in LNM in PTC has not been investigated.</p></abstract><kwd-group kwd-group-type="author"><kwd>Papillary thyroid carcinoma</kwd><kwd>Lymph node</kwd><kwd>MicroRNA</kwd><kwd>Gene expression</kwd></kwd-group><funding-group><award-group id="fund-1"><funding-source>Fundamental Research Grant Scheme (FRGS)</funding-source><award-id>FRGS/1/2014/SKK01/UKM/03/1</award-id></award-group><funding-statement>This manuscript was supported by the Fundamental Research Grant Scheme (FRGS) from the Ministry of Education Malaysia (FRGS/1/2014/SKK01/UKM/03/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Papillary thyroid carcinoma (PTC) is the most common malignancy originating from the thyroid. Although the prognosis of PTC is generally good with a high 5-year survival rate, cases demonstrating certain clinicopathological parameters are progressive, have poorer prognosis and are considered as high-risk (<xref rid="ref-38" ref-type="bibr">Ito et al.</xref>, <xref rid="ref-38" ref-type="bibr">2009</xref>). Numerous classification systems for thyroid carcinoma have been established in order to classify high-risk cases such as AMES (<xref rid="ref-10" ref-type="bibr">Cady &#x00026; Rosai</xref>, <xref rid="ref-10" ref-type="bibr">1988</xref>), AGES (<xref rid="ref-32" ref-type="bibr">Hay et al.</xref>, <xref rid="ref-32" ref-type="bibr">1987</xref>), MACIS (<xref rid="ref-31" ref-type="bibr">Hay et al.</xref>, <xref rid="ref-31" ref-type="bibr">1993</xref>) as well as TNM (<xref rid="ref-64" ref-type="bibr">Sobin &#x00026; Wittekind</xref>, <xref rid="ref-64" ref-type="bibr">2002</xref>; <xref rid="ref-2" ref-type="bibr">AJCC</xref>, <xref rid="ref-2" ref-type="bibr">2010</xref>). The TNM classification is the most recent classification system and is based on size and extrathyroid extension (T), lymph node involvement (N), distant metastasis (M) and patient&#x02019;s age.</p><p>MicroRNAs (miRNAs), firstly identified in <italic>Caenorhabditis elegans</italic>, are a class of endogenous (non-protein-coding), 19&#x02013;24 nucleotides single-stranded RNAs that derive from a stem-loop precursor to inhibit gene expression by binding primarily to the 3&#x02032;-UTR of specific &#x02018;target&#x02019; messenger RNA (mRNAs). MiRNAs that bind with perfect or nearly perfect complementarity to protein-coding mRNA sequences induce the RNA-mediated interference (RNAi) pathway, resulting in the disruption of mRNA stability and/or translation (<xref rid="ref-5" ref-type="bibr">Bartel</xref>, <xref rid="ref-5" ref-type="bibr">2009</xref>). Dysregulation of miRNAs expression in human cancers have been demonstrated by many studies (<xref rid="ref-37" ref-type="bibr">Iorio &#x00026; Croce</xref>, <xref rid="ref-37" ref-type="bibr">2012</xref>). Through expression profiling studies, miRNAs were shown to be linked to tumor development, tumor progression, and response to treatment, signifying their potential use as biomarkers for diagnosis and prognosis (<xref rid="ref-37" ref-type="bibr">Iorio &#x00026; Croce</xref>, <xref rid="ref-37" ref-type="bibr">2012</xref>). MiRNAs have also been shown function as biomarkers in predicting lymph node metastasis (LNM). There was a positive correlation between high hsa-miR-21 expression with tumor stage and LNM in patients with breast cancer (<xref rid="ref-71" ref-type="bibr">Yan et al.</xref>, <xref rid="ref-71" ref-type="bibr">2008</xref>), and the development of distant metastases in colorectal cancer patients (<xref rid="ref-63" ref-type="bibr">Slaby et al.</xref>, <xref rid="ref-63" ref-type="bibr">2007</xref>). Most recently, hsa-miR-1207-5p was suggested as a useful biomarker in the prediction of LNM in gastric cancer (<xref rid="ref-34" ref-type="bibr">Huang et al.</xref>, <xref rid="ref-34" ref-type="bibr">2015</xref>) and head and neck cancer (<xref rid="ref-17" ref-type="bibr">De Carvalho et al.</xref>, <xref rid="ref-17" ref-type="bibr">2015</xref>).</p><p>The current approach of miRNA target gene prediction via <italic>in silico</italic> analysis is built upon sequence similarity search and thermodynamic stability (<xref rid="ref-3" ref-type="bibr">Alexiou et al.</xref>, <xref rid="ref-3" ref-type="bibr">2009</xref>). Nevertheless, it is acknowledged that the results of <italic>in silico</italic> target prediction algorithms suffer from very low specificity (<xref rid="ref-3" ref-type="bibr">Alexiou et al.</xref>, <xref rid="ref-3" ref-type="bibr">2009</xref>). The combination of <italic>in silico</italic> target predictions with miRNA and gene expression profiles has been proven to improve the identification of functional miRNA-target gene relationships (<xref rid="ref-54" ref-type="bibr">Nunez-Iglesias et al.</xref>, <xref rid="ref-54" ref-type="bibr">2010</xref>; <xref rid="ref-50" ref-type="bibr">Ma et al.</xref>, <xref rid="ref-50" ref-type="bibr">2011</xref>). As miRNAs act prevalently through degradation of the target genes, expression profiles of miRNA and target genes/transcripts are predicted to be inversely correlated (<xref rid="ref-8" ref-type="bibr">Bisognin et al.</xref>, <xref rid="ref-8" ref-type="bibr">2012</xref>). Another regulatory component, the transcription factors (TF), has also been shown to activate or repress miRNA expression level, further adding to the complexity of gene regulation. Efforts have been made to comprehend the mechanism of miRNAs in decreasing target genes expression; however the study of miRNA regulation by TFs (TF&#x02013;miRNA regulation) is rather limited (<xref rid="ref-68" ref-type="bibr">Wang et al.</xref>, <xref rid="ref-68" ref-type="bibr">2010a</xref>).</p><p>The Cancer Genome Atlas (TCGA) Research Network recently published a molecular characterization of 507 PTCs and 59 matched normal adjacent tissues with respect to genomic, transcriptomic and proteomic signatures together with DNA methylation profiles, clinical and pathological features (<xref rid="ref-11" ref-type="bibr">Cancer Genome Atlas Research Network</xref>, <xref rid="ref-11" ref-type="bibr">2014</xref>). Data were collected through several studies across different institutions, thus creating a comprehensive dataset of PTC samples. Through unsupervised clustering methods, TCGA yielded six subtypes for miRNA expression and five for gene expression. However, miRNA and gene expression profiles between PTC with and without LNM were not comprehensively discussed. Here we reanalyzed these TCGA datasets on PTC with the aim of identifying differentially expressed miRNAs/genes in PTC patients with LNM-positive (LNM-P) as compared to lymph node negative (LNN) PTC patients and to investigate the miRNA-gene-TF regulatory circuit that governs LNM in PTC.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>TCGA papillary thyroid cancer dataset</title><p>We used the TCGA-generated microRNA sequencing (miRNAseq) and mRNAseq data for 495 tumors and 59 normal thyroid samples (<xref rid="ref-11" ref-type="bibr">Cancer Genome Atlas Research Network</xref>, <xref rid="ref-11" ref-type="bibr">2014</xref>). Metadata containing clinical information including <italic>BRAF</italic> V600E mutation status was obtained from cBioPortal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/study.do?cancer_study_id=thca_tcga_pub#clinical">http://www.cbioportal.org/study.do?cancer_study_id=thca_tcga_pub#clinical</ext-link>) while miRNAseq and mRNAseq of 507 PTC patients were obtained from the TCGA Data Portal (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm">https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm</ext-link>) (accessed from March 27, 2015 to May 25, 2015). Information were available for 507 PTC patients. The list of patients from the metadata was then filtered for PTC patients with N0, N1, N1a, and N1b, resulting in a total of 421 PTC patients out of the 507 patients (86 patients were excluded due to unavailability of node status). The clinical parameters are presented in <xref ref-type="table" rid="table-1">Table 1</xref>.</p><table-wrap id="table-1" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.2119/table-1</object-id><label>Table 1</label><caption><title>Patient characteristics and integrated profiles in the TCGA PTC cohort.</title></caption><alternatives><graphic xlink:href="peerj-04-2119-g007"/><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">PTC LNN</th><th align="center" colspan="3" rowspan="1">PTC LNM-P</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">N0 (<italic>n</italic> = 213)</th><th rowspan="1" colspan="1">N1 (<italic>n</italic> = 53)</th><th rowspan="1" colspan="1">N1a (<italic>n</italic> = 86)</th><th rowspan="1" colspan="1">N1b (<italic>n</italic> = 66)</th></tr></thead><tbody><tr style="background-color:#C4E8FA;"><td rowspan="1" colspan="1">Age range (years)</td><td rowspan="1" colspan="1">15&#x02013;85</td><td rowspan="1" colspan="1">19&#x02013;83</td><td rowspan="1" colspan="1">18&#x02013;83</td><td rowspan="1" colspan="1">19&#x02013;89</td></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Mean age</td><td rowspan="1" colspan="1">49.4</td><td rowspan="1" colspan="1">41.9</td><td rowspan="1" colspan="1">43.5</td><td rowspan="1" colspan="1">48.4</td></tr><tr style="background-color:#E0F2F8;"><td rowspan="1" colspan="1">Gender (<italic>n</italic>)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr style="background-color:#E0F2F8;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">50 (23.5%)</td><td rowspan="1" colspan="1">14 (26.4%)</td><td rowspan="1" colspan="1">25 (29.1%)</td><td rowspan="1" colspan="1">27 (40.9%)</td></tr><tr style="background-color:#E0F2F8;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">163 (76.5%)</td><td rowspan="1" colspan="1">39 (73.6%)</td><td rowspan="1" colspan="1">61 (70.9%)</td><td rowspan="1" colspan="1">39 (59.1%)</td></tr><tr style="background-color:#C4E8FA;"><td rowspan="1" colspan="1">Disease free status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Recurred/progressed</td><td rowspan="1" colspan="1">5 (2.3%)</td><td rowspan="1" colspan="1">7 (13.2%)</td><td rowspan="1" colspan="1">6 (7%)</td><td rowspan="1" colspan="1">6 (9.1%)</td></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Disease free</td><td rowspan="1" colspan="1">178 (83.6%)</td><td rowspan="1" colspan="1">41 (77.4%)</td><td rowspan="1" colspan="1">75 (87.2%)</td><td rowspan="1" colspan="1">47 (71.2%)</td></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">30 (14.1%)</td><td rowspan="1" colspan="1">5 (9.4%)</td><td rowspan="1" colspan="1">5 (5.8%)</td><td rowspan="1" colspan="1">13 (19.7%)</td></tr><tr style="background-color:#E0F2F8;"><td rowspan="1" colspan="1">Disease free (range in months)</td><td rowspan="1" colspan="1">0.03&#x02013;155</td><td rowspan="1" colspan="1">0&#x02013;131</td><td rowspan="1" colspan="1">0&#x02013;157</td><td rowspan="1" colspan="1">0.2 &#x02013;46</td></tr><tr style="background-color:#E0F2F8;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Mean disease-free survival</td><td rowspan="1" colspan="1">23.6 (<italic>n</italic> = 183)</td><td rowspan="1" colspan="1">34.5 (<italic>n</italic> = 48)</td><td rowspan="1" colspan="1">21.5 (<italic>n</italic> = 81)</td><td rowspan="1" colspan="1">13.5 (<italic>n</italic> = 53)</td></tr><tr style="background-color:#C4E8FA;"><td rowspan="1" colspan="1">Overall survival status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Deceased</td><td rowspan="1" colspan="1">35 (16.4%)</td><td rowspan="1" colspan="1">12 (22.6%)</td><td rowspan="1" colspan="1">11 (12.8%)</td><td rowspan="1" colspan="1">19 (28.8%)</td></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Alive</td><td rowspan="1" colspan="1">178 (83.6%)</td><td rowspan="1" colspan="1">41 (77.6%)</td><td rowspan="1" colspan="1">75 (87.2%)</td><td rowspan="1" colspan="1">47 (71.2%)</td></tr><tr style="background-color:#E0F2F8;"><td rowspan="1" colspan="1">Overall survival (range in months)</td><td rowspan="1" colspan="1">0.03&#x02013;155</td><td rowspan="1" colspan="1">0&#x02013;131</td><td rowspan="1" colspan="1">0&#x02013;157</td><td rowspan="1" colspan="1">0.2 &#x02013;97.7</td></tr><tr style="background-color:#E0F2F8;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Mean overall survival</td><td rowspan="1" colspan="1">24.3 (<italic>n</italic> = 182)</td><td rowspan="1" colspan="1">35.2 (<italic>n</italic> = 43)</td><td rowspan="1" colspan="1">21.4 (<italic>n</italic> = 75)</td><td rowspan="1" colspan="1">15.2 (<italic>n</italic> = 50)</td></tr><tr style="background-color:#C4E8FA;"><td rowspan="1" colspan="1">Extrathyroidal extension</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">160 (75.1%)</td><td rowspan="1" colspan="1">31 (58.5%)</td><td rowspan="1" colspan="1">49 (57%)</td><td rowspan="1" colspan="1">37 (56.1%)</td></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Minimal (T3)</td><td rowspan="1" colspan="1">42 (19.7%)</td><td rowspan="1" colspan="1">14 (26.4%)</td><td rowspan="1" colspan="1">33 (38.4%)</td><td rowspan="1" colspan="1">23 (34.8%)</td></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Moderate/advanced (T4a)</td><td rowspan="1" colspan="1">3 (1.4%)</td><td rowspan="1" colspan="1">5 (9.4%)</td><td rowspan="1" colspan="1">1 (1.2%)</td><td rowspan="1" colspan="1">4 (6.1%)</td></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Very advanced (T4b)</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">1 (1.9%)</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">0 (0%)</td></tr><tr style="background-color:#C4E8FA;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">8 (3.8%)</td><td rowspan="1" colspan="1">2 (3.8%)</td><td rowspan="1" colspan="1">3 (3.5%)</td><td rowspan="1" colspan="1">2 (3%)</td></tr><tr style="background-color:#E0F2F8;"><td rowspan="1" colspan="1">BRAF status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr style="background-color:#E0F2F8;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Mutated</td><td rowspan="1" colspan="1">94 (44.1%)</td><td rowspan="1" colspan="1">25 (47.2%)</td><td rowspan="1" colspan="1">53 (61.6%)</td><td rowspan="1" colspan="1">32 (48.9%)</td></tr><tr style="background-color:#E0F2F8;"><td style="padding-left:1pc;" rowspan="1" colspan="1">Wild type</td><td rowspan="1" colspan="1">119 (55.9%)</td><td rowspan="1" colspan="1">28 (52.8%)</td><td rowspan="1" colspan="1">33 (38.4%)</td><td rowspan="1" colspan="1">34 (51.5%)</td></tr></tbody></table></alternatives></table-wrap><p>Only samples with paired miRNAseq and mRNAseq data were selected, resulting in exclusion of additional three patients. In the end, we obtained a total of 418 patients&#x02019; dataset which includes 213 patients with PTC LNN (N0) and 205 PTC LNM-P (53 patients with N1, 86 patients with N1a, 66 patients with N1b) (<xref ref-type="supplementary-material" rid="supp-1">Table S1</xref>). Combined with 59 normal thyroid tissues, the total of datasets included in this study were 477. The miRNA and gene expression datasets consisting of 1,046 human miRNAs and 20,531 genes, respectively, were used for subsequent analysis.</p></sec><sec><title>Survival analyses</title><p>Kaplan&#x02013;Meier survival analysis was carried out on disease-free and overall survival duration of TCGA PTC patients for whom follow-up details were available. Overall survival is defined as the duration from the date of diagnosis to death (due to all causes) while disease-free survival is defined as the duration from the date of the diagnosis to the date of recurrence, second cancer, or death due to all causes (whichever occurred first) (<xref rid="ref-61" ref-type="bibr">Schvartz et al.</xref>, <xref rid="ref-61" ref-type="bibr">2012</xref>). Curves were compared by univariate (log-rank) analysis. Statistical analyses were performed using GraphPad Prism version 6 (GraphPad, San Diego, CA, USA). <italic>P</italic> values &#x02264;0.05 were considered significant.</p></sec><sec><title>Clinical specimen and total RNA isolation</title><p>Ten fresh frozen tumour-adjacent normal PTC tissues specimens from UKMMC-UMBI Biobank were subjected to cryosectioning and Haematoxylin and Eosin (H&#x00026;E) staining. This part of research was approved by the Universiti Kebangsaan Malaysia Research Ethics Committee (UKMREC) (reference: UKM 1.5.3.5/244/UMBI-2015-002). A written informed consent had been signed by these 10 subjects included in validation phase according to institution&#x02019;s rules and regulations. All the slides were reviewed by the pathologist to assess the percentage of tumour cells and normal cells. Only tumour tissues which contain &#x0003e;80% cancer cells and normal tissues with &#x0003c;20% necrosis were subjected to nucleic acid extraction. Total RNA including miRNA was isolated from the frozen samples using AllPrep DNA/RNA/miRNA Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer&#x02019;s protocol. The total RNA quality and quantity were assessed via absorbance spectrophotometry on a Nanodrop 1000 instrument (Thermo Scientific, Wilmington, DE, USA) and Qubit&#x02122; fluorometer (Invitrogen, USA). Integrity of RNA was assessed using Eukaryote Total RNA Nano chip on Bioanalyzer 2100 (Agilent Technologies, Santa Clara, USA). Only total RNA with RNA Integrity Number (RIN) of at least 6 were used for subsequent steps. Eukaryote Small RNA chip (Agilent Technologies, Santa Clara, USA) was used for determination of concentration and percentage of small RNA.</p></sec><sec><title>Library preparation and next generation sequencing</title><p>MiRNA libraries were prepared using Illumina Truseq Small RNA library preparation kit (Illumina, SanDiego, USA) following manufacturer&#x02019;s protocol. Briefly, 3&#x02032; and 5&#x02032; adapters were sequentially ligated to the ends of small RNAs fractionated from 1 &#x000b5;g of total RNA, and reverse transcribed to generate cDNA. The cDNA was amplified using a common primer complementary to the 3&#x02032; adapter, and a primer containing 1 of 48 index sequences. Samples were size-selected (145&#x02013;160 bp fragments) on a 6% polyacrylamide gel, purified, quantified and pooled for multiplexed sequencing. The resulting pooled libraries were normalized to 2 nM and were hybridized to oligonucleotide-coated single-read flow cells for cluster generation using HiSeq<sup>&#x000ae;</sup> Rapid SR Cluster Kit v2 on Hiseq 2500. Subsequently the clustered pooled microRNA libraries were sequenced on the HiSeq 2500 for 50 sequencing cycles using HiSeq<sup>&#x000ae;</sup> Rapid SBS Kit v2 (50 Cycle). Base calling was performed using CASAVA (v.1.8.2) (Illumina, San Diego, CA, USA) and short-read sequences in FASTQ format were used for downstream analysis.</p></sec><sec><title>Bioinformatics analyses</title><p>The miRNASeq and RNASeq V2 level 3 data from TCGA were used exclusively. The normalised expression (reads per million or RPM) of all miRNAs was log<sub>2</sub>-transformed and used for fold change calculation. The RNAseq by Expectation-Maximization (RSEM) values (from files with the extension .rsem.genes.results) were used to quantify messenger RNA (mRNA) expression levels. The RSEM algorithm is a statistical model that estimates RNA expression levels from RNA sequencing counts (<xref rid="ref-47" ref-type="bibr">Li &#x00026; Dewey</xref>, <xref rid="ref-47" ref-type="bibr">2011</xref>). We then performed the Students&#x02019; unpaired <italic>t</italic>-test with a Benjamini Hochberg false discovery rate (FDR) multiple testing correction and log<sub>2</sub> fold change calculation using Bioconductor version 3.1 (BiocInstaller 1.18.2) (<xref rid="ref-25" ref-type="bibr">Gentleman et al.</xref>, <xref rid="ref-25" ref-type="bibr">2004</xref>) in R version 3.2.0 (<xref rid="ref-58" ref-type="bibr">R Development Core Team</xref>, <xref rid="ref-58" ref-type="bibr">2008</xref>) (<xref ref-type="supplementary-material" rid="supp-4">Files S1</xref> and <xref ref-type="supplementary-material" rid="supp-6">S2</xref>). Downregulated genes will have negative log<sub>2</sub> values while upregulated genes will have positive log<sub>2</sub> values. Statistical significance is denoted as <italic>p</italic> &#x02264; 0.05. Heatmaps were created using GeneE from the Broad Institute (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/cancer/software/GENE-E">http://www.broadinstitute.org/cancer/software/GENE-E</ext-link>) while Venn diagrams were created using Venn online tool (<ext-link ext-link-type="uri" xlink:href="http://bioinformatics.psb.ugent.be/webtools/Venn">http://bioinformatics.psb.ugent.be/webtools/Venn</ext-link>). All other figures were created or labelled using Adobe Photoshop.</p><p>Analysis of the miRNAseq data from our in house experiment were performed using BaseSpace miRNA Analysis app version 1.0.0 (Illumina, San Diego, CA, USA) using the default setting. Briefly, adapters were trimmed using cutadapt, the trimmed reads were mapped on miRNA precursors using SHRiMPS aligner, the reads associated to mature miRNAs were counted and differential expression between experimental conditions were analysed using DESeq2 (<xref rid="ref-16" ref-type="bibr">Cordero et al.</xref>, <xref rid="ref-16" ref-type="bibr">2012</xref>). The expression, log<sub>2</sub> fold change and adjusted <italic>p</italic>-value of hsa-miR-146b, hsa-miR-375, hsa-miR-31, hsa-miR-7-2 and hsa-miR-204 were then extracted from the overall results.</p></sec><sec><title>Pathway enrichment analysis and integrated analysis of miRNA and gene expression</title><p>The functions and pathways of the differentially expressed genes were annotated and analysed using the annotation tools from the Database for Annotation, Visualization and Integrated Discovery (DAVID) (<xref rid="ref-35" ref-type="bibr">Huang, Sherman &#x00026; Lempicki</xref>, <xref rid="ref-35" ref-type="bibr">2009a</xref>; <xref rid="ref-36" ref-type="bibr">Huang, Sherman &#x00026; Lempicki</xref>, <xref rid="ref-36" ref-type="bibr">2009b</xref>) according to the steps described in these publications. The identified genes were also jointly annotated against the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<xref rid="ref-39" ref-type="bibr">Kanehisa &#x00026; Goto</xref>, <xref rid="ref-39" ref-type="bibr">2000</xref>). The genes that were annotated in the KEGG database as being involved in signaling pathways were subjected to further analysis. Pathways with Benjamini-adjusted <italic>p</italic> value &#x02264;0.05 were considered to be statistically significant.</p><p>Integration of the miRNAs dataset with gene expression dataset and calculation of correlation were performed in MAGIA2, a web tool for the integrated analysis of target predictions, miRNA and gene expression data (<xref rid="ref-8" ref-type="bibr">Bisognin et al.</xref>, <xref rid="ref-8" ref-type="bibr">2012</xref>). MiRNA target predictions include transcription factor binding sites (TFBS) within miRNA and gene promoters. In this analysis, matched expression data matrices of significantly dysregulated miRNAs and genes (BH adjusted <italic>p</italic> value &#x02264;0.05) were uploaded for integrated analysis. EntrezGene IDs and DIANA-microT (<xref rid="ref-52" ref-type="bibr">Maragkakis et al.</xref>, <xref rid="ref-52" ref-type="bibr">2009</xref>) target prediction algorithms were selected. Anticorrelated expressions were investigated between miRNA and their putative target genes using Pearson correlation measure.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>The effect of lymph node status on survival duration of TCGA PTC patients</title><p>Overall survival in PTC patients was not influenced by LNM status (<xref ref-type="fig" rid="fig-1">Fig. 1A</xref>); however, PTC patients with LNM has significantly shorter disease-free survival rate compared to PTC patients without LNM (Log-rank Mantel Cox test, <italic>p</italic> = 0.0049; <xref ref-type="fig" rid="fig-1">Fig. 1B</xref>).</p><fig id="fig-1" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.2119/fig-1</object-id><label>Figure 1</label><caption><title>Survival analysis of PTC with LNM and PTC without LNM.</title></caption><graphic xlink:href="peerj-04-2119-g001"/></fig></sec><sec><title>Differentially expressed miRNAs</title><p>We identified 181 miRNAs which were significantly differentially expressed in PTC LNM-P versus PTC LNN (BH corrected <italic>p</italic> value &#x02264;0.05). Among the 181 miRNAs significantly expressed in PTC LNM-P versus PTC LNN, 110 were upregulated and 71 were downregulated (<xref ref-type="supplementary-material" rid="supp-2">Table S2</xref>). <xref ref-type="fig" rid="fig-2">Figure2</xref> illustrates a heatmap representing the expression levels of 181 deregulated miRNAs in PTC LNM-P versus PTC LNN. The list of top deregulated miRNAs includes hsa-miR-146b, hsa-miR-375, hsa-miR-31, hsa-miR-7-2 and hsa-miR-204 (log<sub>2</sub> fold change 1.7, 1.3, 1, &#x02212;1.1 and &#x02212;1.3, respectively, <xref ref-type="fig" rid="fig-3">Fig. 3</xref>). On the other hand, 395 miRNAs were differentially expressed between PTC LNM-P and normal thyroid while 400 miRNAs were differentially expressed between PTC LNN and normal thyroid (<xref ref-type="supplementary-material" rid="supp-8">Figs. S1</xref> and <xref ref-type="supplementary-material" rid="supp-9">S2</xref>, respectively). The list of miRNAs significantly deregulated in PTC LNM-P and PTC LNN compared to normal thyroid is included in <xref ref-type="supplementary-material" rid="supp-3">Table S3</xref>.</p><fig id="fig-2" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.2119/fig-2</object-id><label>Figure 2</label><caption><title>Heat map of the 181 differentially expressed miRNAs in PTC LNM-P and LNN (Student&#x02019;s <italic>T</italic>-test with BH corrected <italic>p</italic> value &#x02264; 0.05).</title></caption><graphic xlink:href="peerj-04-2119-g002"/></fig><fig id="fig-3" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.2119/fig-3</object-id><label>Figure 3</label><caption><title>Expression levels of five selected miRNAs deregulated in PTC.</title><p>Boxplots (A) illustrate log<sub>2</sub> normalized miRNA reads in PTC LNM-P, PTC LNN and normal thyroid. Table (B) showing log2 fold change and <italic>p</italic> value of selected miRNAs in PTC LNM-P compared to PTC LNN.</p></caption><graphic xlink:href="peerj-04-2119-g003"/></fig><p>We then determine the expression of these top deregulated miRNAs in a small set of validation experiment consisted of five pairs of tumour-adjacent normal from each PTC LNM-P and PTC LNN cases (total of 20 samples comprised of five PTC LNM-P, five PTC LNN and 10 adjacent normal thyroid tissues from each patient). As illustrated in <xref ref-type="fig" rid="fig-3">Fig. 3B</xref>, hsa-miR-146b was significantly upregulated in PTC LNM-P versus adjacent normal thyroid (log<sub>2</sub> fold change 6.0) and in PTC LNN versus adjacent normal thyroid (log<sub>2</sub> fold change 4.7). Similar trends were observed for hsa-miR-375, hsa-miR-31 and hsa-miR-204 in PTC LNM-P versus adjacent normal thyroid (log<sub>2</sub> fold change 3.6, 3.1 and &#x02212;3.4, respectively, <xref ref-type="fig" rid="fig-3">Fig. 3B</xref>). However, downregulation of hsa-miR-7-2 in PTC LNM-P versus adjacent normal thyroid did not reach statistical significance. On the other hand, expression of hsa-miR-375, hsa-miR-7-2 and hsa-miR-204 in PTC LNN versus adjacent normal thyroid were in concordance with our analysis using the TCGA data (log<sub>2</sub> fold change 3.6, &#x02212;2.3 and &#x02212;2.7, <xref ref-type="fig" rid="fig-3">Fig. 3B</xref>).</p><p>These findings did not deviate much from our analysis using the TCGA PTC data with the exception to hsa-miR-7-2 in PTC LNM-P versus adjacent normal thyroid and hsa-miR-31 in PTC LNN versus adjacent normal thyroid which failed to reach statistical significance (<xref ref-type="supplementary-material" rid="supp-2">Table S2</xref>). This could be explained due to the fact that our validation samples were tumour-adjacent normal tissues while TCGA PTC specimens were of unpaired normal tissues. However, the differential expression of these five top deregulated miRNAs did not reach statistical significant when we compared between PTC LNM-P and PTC LNN (<xref ref-type="fig" rid="fig-3">Fig. 3B</xref>). This might be due to small sample size in our validation study.</p></sec><sec><title>Differentially expressed genes</title><p>Initial filtering revealed 8,611 significantly deregulated genes in PTC LNM-P versus PTC LNN, 14,192 genes in PTC LNM-P versus normal thyroid and 13,392 genes in PTC LNN versus normal thyroid. There were 4,135 upregulated and 4,476 downregulated genes in PTC LNM-P relative to PTC LNN. By increasing the stringency of selection to genes with log<sub>2</sub> fold change &#x02265;1 or &#x02264; &#x02212; 1, 407 genes were identified as strongly deregulated. Among the strongly deregulated genes were <italic>SFTPB</italic>, <italic>CLDN10</italic>, <italic>DIO1</italic> and <italic>MT1G</italic> (log<sub>2</sub> fold change 3.1, 2.9, &#x02212;2.2 and &#x02212;2.5 respectively, <xref ref-type="supplementary-material" rid="supp-5">Table S4</xref>). Various cancer-related genes were also differentially expressed significantly, including <italic>BRAF</italic>, <italic>BRCA2</italic>, <italic>VEGFA</italic>, <italic>VEGFB</italic>, <italic>RET</italic>, <italic>PIK3CA</italic>, <italic>CTNNB1</italic> and <italic>GNAS</italic> (<xref ref-type="supplementary-material" rid="supp-5">Table S4</xref>).</p></sec><sec><title>Enriched pathways in PTC LNM-P</title><p>The significantly dysregulated genes in PTC LNM-P versus PTC LNN were mainly enriched in 12 KEGG pathways including oxidative phosphorylation (OxPhos), Parkinson&#x02019;s disease, focal adhesion, Alzheimer&#x02019;s disease, valine, leucine and isoleucine degradation, pathways in cancer, cell adhesion molecules (CAMs), leukocyte transendothelial migration, cytokine&#x02013;cytokine receptor interaction, small cell lung cancer, Huntington&#x02019;s disease and extracellular matrix receptor interaction (<xref ref-type="fig" rid="fig-4">Fig. 4A</xref>). When we overlapped the results from the three comparison groups (PTC LNM-P versus PTC LNN, PTC LNM-P versus normal thyroid and PTC LNN versus normal thyroid), four unique pathways potentially involved in metastasis to the lymph nodes were significantly enriched, namely, oxidative phosphorylation (OxPhos), cell adhesion molecules (CAMs), leukocyte transendothelial migration and cytokine&#x02013;cytokine receptor interaction pathways (<xref ref-type="fig" rid="fig-4">Fig. 4A</xref>). The oxidative phosphorylation pathway was the most significantly perturbed (<italic>p</italic> = 4.70E&#x02212;06) with general downregulation of 90 OxPhos-related genes (<xref ref-type="fig" rid="fig-5">Fig. 5</xref>). Focal adhesion and pathways in cancer were commonly enriched in all the three group comparisons. Pathways in cancer is a collection of general cancer-related pathways and is an indication that many essential carcinogenic processes may be under the influence of dysregulated miRNAs (<xref rid="ref-57" ref-type="bibr">Pizzini et al.</xref>, <xref rid="ref-57" ref-type="bibr">2013</xref>). On the other hand, ECM-receptor interaction pathway and the valine, leucine and isoleucine degradation pathway were commonly enriched only in PTC LNM-P versus PTC LNN and PTC LNM-P versus normal thyroid but were not enriched in PTC LNN versus normal thyroid (<xref ref-type="fig" rid="fig-4">Fig. 4B</xref>).</p><fig id="fig-4" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.2119/fig-4</object-id><label>Figure 4</label><caption><title>Significantly enriched pathways in PTCs.</title><p>Significant KEGG pathway associations to 8611 significantly deregulated genes in PTC LNM-P versus PTC LNN, 14,192 genes in PTC LNM-P versus normal thyroid and 13,392 genes in PTC LNN versus normal thyroid.</p></caption><graphic xlink:href="peerj-04-2119-g004"/></fig><fig id="fig-5" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.2119/fig-5</object-id><label>Figure 5</label><caption><title>KEGG pathway map illustrating oxidative phosphorylation in human.</title><p>The OxPhos-related genes significantly altered in PTC LNM-P compared to PTC LNN were depicted with red star. Pathway figure was obtained from KEGG (Kyoto Encyclopedia of Genes and Genomes) (<xref rid="ref-39" ref-type="bibr">Kanehisa &#x00026; Goto</xref>, <xref rid="ref-39" ref-type="bibr">2000</xref>; <xref rid="ref-40" ref-type="bibr">Kanehisa et al.</xref>, <xref rid="ref-40" ref-type="bibr">2016</xref>) in DAVID analysis.</p></caption><graphic xlink:href="peerj-04-2119-g005"/></fig></sec><sec><title>Integrated mixed regulatory circuits, involving miRNAs, genes and TFs in PTC LNM-P</title><p>To obtain a more comprehensive insight into the molecular circuits behind LNM in PTC, we focused on functional miRNA-target relationships by performing an <italic>in silico</italic> integration between differentially expressed miRNAs and genes using MAGIA2. Transcription factors-miRNA (TF-miRNA) prediction was based on mirGen2.0 database (<xref rid="ref-23" ref-type="bibr">Friard et al.</xref>, <xref rid="ref-23" ref-type="bibr">2010</xref>) and TransmiR (<xref rid="ref-68" ref-type="bibr">Wang et al.</xref>, <xref rid="ref-68" ref-type="bibr">2010a</xref>), whereas the TF&#x02013;gene interactions were acquired from the &#x02018;TFBS conserved&#x02019; track of the University of California Santa Cruz (UCSC) genome annotation for humans (version hg19) (<xref rid="ref-8" ref-type="bibr">Bisognin et al.</xref>, <xref rid="ref-8" ref-type="bibr">2012</xref>). Our results show that 12 miRNAs are involved in the strongest 200 interactions and they were identified as significant by MAGIA2. Hsa-miR-147b, hsa-miR-301b, hsa-miR-375, hsa-miR-496, hsa-miR-543, hsa-miR-577, hsa-miR-765, hsa-miR-892a, hsa-miR-934, hsa-miR-935, hsa-miR-940 and hsa-miR-944 were predicted to activate or inhibit 3,746 genes and 1,987 TFs (<xref ref-type="fig" rid="fig-6">Fig. 6</xref>). Hsa-miR-577 and hsa-miR-147b consistently appeared in the top 20 regulatory circuits across all group comparisons. Interestingly, hsa-miR-301b appeared in both of the top 20 circuits in PTC LNM-P versus PTC LNN or normal thyroid but was absent in PTC LNN versus normal thyroid (<xref ref-type="supplementary-material" rid="supp-10">Fig. S3</xref>).</p><fig id="fig-6" orientation="portrait" position="float"><object-id pub-id-type="doi">10.7717/peerj.2119/fig-6</object-id><label>Figure 6</label><caption><title>Grand view of top 200 regulatory circuits constructed using significantly dysregulated miRNAs and genes in PTC LNM-P compared to PTC LNN.</title></caption><graphic xlink:href="peerj-04-2119-g006"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, we explored the landscape of miRNA and mRNA expression of PTC using data obtained from the TCGA THCA project aiming to identify key pathways involved in lymph node metastasis. Our analysis revealed 110 upregulated miRNAs and 71 downregulated miRNAs in PTC LNM-P versus PTC LNN. The top deregulated miRNAs includes hsa-miR-146b, hsa-miR-375, hsa-miR-31, hsa-miR-7-2 and hsa-miR-204. Our findings are supported by several other similar studies, and in particular hsa-miR-146b, which was reported to be upregulated in PTC LNM-P versus PTC LNN (<xref rid="ref-46" ref-type="bibr">Lee et al.</xref>, <xref rid="ref-46" ref-type="bibr">2013</xref>; <xref rid="ref-72" ref-type="bibr">Yang et al.</xref>, <xref rid="ref-72" ref-type="bibr">2013</xref>; <xref rid="ref-1" ref-type="bibr">Acibucu et al.</xref>, <xref rid="ref-1" ref-type="bibr">2014</xref>; <xref rid="ref-18" ref-type="bibr">Deng et al.</xref>, <xref rid="ref-18" ref-type="bibr">2015</xref>).</p><p>Hsa-miR-146 is one of the widely studied miRNAs in thyroid cancers and has been shown to be frequently upregulated in PTC (<xref rid="ref-33" ref-type="bibr">He et al.</xref>, <xref rid="ref-33" ref-type="bibr">2005</xref>; <xref rid="ref-56" ref-type="bibr">Pallante et al.</xref>, <xref rid="ref-56" ref-type="bibr">2006</xref>; <xref rid="ref-67" ref-type="bibr">Tetzlaff et al.</xref>, <xref rid="ref-67" ref-type="bibr">2007</xref>; <xref rid="ref-13" ref-type="bibr">Chen et al.</xref>, <xref rid="ref-13" ref-type="bibr">2008</xref>; <xref rid="ref-74" ref-type="bibr">Yip et al.</xref>, <xref rid="ref-74" ref-type="bibr">2011</xref>; <xref rid="ref-14" ref-type="bibr">Chou et al.</xref>, <xref rid="ref-14" ref-type="bibr">2010</xref>; <xref rid="ref-15" ref-type="bibr">Chou et al.</xref>, <xref rid="ref-15" ref-type="bibr">2013</xref>; <xref rid="ref-65" ref-type="bibr">Sun et al.</xref>, <xref rid="ref-65" ref-type="bibr">2013</xref>), anaplastic thyroid cancer (<xref rid="ref-22" ref-type="bibr">Fassina et al.</xref>, <xref rid="ref-22" ref-type="bibr">2014</xref>) and follicular thyroid cancer (FTC) (<xref rid="ref-70" ref-type="bibr">Wojtas et al.</xref>, <xref rid="ref-70" ref-type="bibr">2014</xref>). Functional analyses of hsa-miR-146 revealed its involvement in various cellular functions including migration, invasion, proliferation, colony-forming ability, cell cycle, and resistance to chemotherapy-induced apoptosis in <italic>BRAF</italic>-mutated cell lines (<xref rid="ref-15" ref-type="bibr">Chou et al.</xref>, <xref rid="ref-15" ref-type="bibr">2013</xref>; <xref rid="ref-18" ref-type="bibr">Deng et al.</xref>, <xref rid="ref-18" ref-type="bibr">2015</xref>; <xref rid="ref-26" ref-type="bibr">Geraldo, Yamashita &#x00026; Kimura</xref>, <xref rid="ref-26" ref-type="bibr">2012</xref>). Using multivariate logistic regression analysis, Chou and colleagues, <xref rid="ref-15" ref-type="bibr">(2013)</xref> demonstrated that increased hsa-miR-146b expression is one of the independent risk factors for poor prognosis in PTC, implicating the potential of this miRNA as a prognostic marker.</p><p>The genes targeted by hsa-miR-146b are mostly unknown, and to date there are only two genes which has been reported as the direct targets of this miRNA in PTC. <xref rid="ref-26" ref-type="bibr">Geraldo, Yamashita &#x00026; Kimura</xref> (<xref rid="ref-26" ref-type="bibr">2012</xref>) reported <italic>SMAD4</italic>, an important member of the transforming growth factor <italic>&#x003b2;</italic> (TGF-<italic>&#x003b2;</italic>) signaling pathway, as the target of hsa-miR-146b-5p. The direct binding of hsa-miR-146b-5p on the <italic>SMAD4</italic> UTR was confirmed via a luciferase reporter assay and the inhibition of hsa-miR-146b-5p expression resulted in significantly increased SMAD4 gene and protein expression levels in the human PTC cell lines. Furthermore, the inhibition of hsa-miR-146b-5p increased the cellular response to the TGF-<italic>&#x003b2;</italic> anti-proliferative signal, leading to significant reduction of cell proliferation (<xref rid="ref-26" ref-type="bibr">Geraldo, Yamashita &#x00026; Kimura</xref>, <xref rid="ref-26" ref-type="bibr">2012</xref>). In a more recent study, the Zinc Ring Finger 3 (ZNRF3) gene was revealed as a direct target of hsa-miR-146b-5p and this miRNA was shown to stimulate cell migration, invasion and epithelial-to-mesenchymal transition (EMT) by downregulating <italic>ZNRF3</italic> (<xref rid="ref-18" ref-type="bibr">Deng et al.</xref>, <xref rid="ref-18" ref-type="bibr">2015</xref>). Another study showed that <italic>ZNRF3</italic> inhibits Wnt signaling by interacting with FZD and LRP 5/6 complexes, hence promoting Wnt receptor ubiquitination and degradation (<xref rid="ref-30" ref-type="bibr">Hao et al.</xref>, <xref rid="ref-30" ref-type="bibr">2012</xref>). Hsa-miR-146b-5p increases the cell surface levels of FZD6 and LRP6 via suppression of <italic>ZNRF3</italic>, causing enhanced Wnt/<italic>&#x003b2;</italic>-catenin signaling. These findings revealed a novel mechanism of hsa-miR-146b-5p in mediating the induction of EMT and implied the role of <italic>ZNRF3</italic> as a tumor suppressor in PTC (<xref rid="ref-18" ref-type="bibr">Deng et al.</xref>, <xref rid="ref-18" ref-type="bibr">2015</xref>). Additional efforts to identify genes controlled by hsa-miR-146b associated with LNM will eventually revealed new biomarkers that can be utilized to correlate with disease outcome in PTC patients.</p><p>Hsa-miR-204 expression in PTC LNM-P is significantly lower than in PTC LNN. This is the first report showing the downregulation of hsa-miR-204 in PTC LNM-P. This miRNA was also downregulated in PTC compared to adjacent normal thyroid tissue and noncancerous thyroid (<xref rid="ref-66" ref-type="bibr">Swierniak et al.</xref>, <xref rid="ref-66" ref-type="bibr">2013</xref>). It is likely that hsa-miR-204 is downregulated in PTC compared to normal or benign thyroid disease and is further supressed when lymph node metastasis occurs. This miRNA is known as a tumor suppressor miRNA and is downregulated in various cancers including renal clear cell carcinoma (<xref rid="ref-27" ref-type="bibr">Gowrishankar et al.</xref>, <xref rid="ref-27" ref-type="bibr">2014</xref>), minimal deviation adenocarcinoma (MDA) of uterine cervix (<xref rid="ref-44" ref-type="bibr">Lee et al.</xref>, <xref rid="ref-44" ref-type="bibr">2014</xref>) and breast cancer (<xref rid="ref-48" ref-type="bibr">Li et al.</xref>, <xref rid="ref-48" ref-type="bibr">2014</xref>). This miRNA has also been shown to have a prognostic value; low level of hsa-miR-204-5p expression was correlated with LNM, advanced stage and low survival rate in endometrial cancer (<xref rid="ref-4" ref-type="bibr">Bao et al.</xref>, <xref rid="ref-4" ref-type="bibr">2013</xref>), and also poor prognosis in colorectal cancer (<xref rid="ref-73" ref-type="bibr">Yin et al.</xref>, <xref rid="ref-73" ref-type="bibr">2014</xref>). <italic>In vitro</italic> functional analyses revealed the involvement of hsa-miR-204 in inhibiting the clonogenic growth, migration and invasion of endometrial carcinoma cells (<xref rid="ref-4" ref-type="bibr">Bao et al.</xref>, <xref rid="ref-4" ref-type="bibr">2013</xref>). In addition, restoration of hsa-miR-204-5p expression supressed cell proliferation, migration, invasion and induced apoptosis and chemotherapeutic sensitivity in colorectal cancer cell (<xref rid="ref-73" ref-type="bibr">Yin et al.</xref>, <xref rid="ref-73" ref-type="bibr">2014</xref>).</p><p>The validated targets for hsa-miR-204 in PTC are also not well-characterized. To date there is only one study investigating the functional role of hsa-miR-204 in PTC (<xref rid="ref-49" ref-type="bibr">Liu et al.</xref>, <xref rid="ref-49" ref-type="bibr">2015</xref>). Enforced expression of hsa-miR-204-5p inhibited cell proliferation and induced apoptosis and cell cycle arrest in PTC cell lines (TCP-1 and BCPAP). In addition, hsa-miR-204-5p also inhibits PTC cell tumorigenicity <italic>in vivo</italic> (<xref rid="ref-49" ref-type="bibr">Liu et al.</xref>, <xref rid="ref-49" ref-type="bibr">2015</xref>). Bioinformatics prediction analyses using three algorithms (miRanda, Pictar, and TargetScan) revealed the insulin-like growth factor-binding protein 5 (IGFBP5), a gene playing an essential role in carcinogenesis (<xref rid="ref-6" ref-type="bibr">Beattie et al.</xref>, <xref rid="ref-6" ref-type="bibr">2006</xref>), as a potential target of hsa-miR-204-5p. Luciferase reporter assay confirmed the direct binding of hsa-miR-204-5p to the 3&#x02032; UTR of <italic>IGFBP5</italic> (<xref rid="ref-49" ref-type="bibr">Liu et al.</xref>, <xref rid="ref-49" ref-type="bibr">2015</xref>). In the same study, hsa-miR-204-5p and <italic>IGFBP5</italic> expression were also shown to be inversely correlated. Their findings confirmed the role of hsa-miR-204-5p as a tumor suppressor in PTC and revealed the potential use of this miRNA as a therapeutic agent in the treatment of PTC.</p><p>In an attempt to identify genes and pathways associated with mortality in PTC, <xref rid="ref-53" ref-type="bibr">Nilubol et al.</xref> (<xref rid="ref-53" ref-type="bibr">2011</xref>) performed genome-wide expression (GWE) analysis in 64 PTC patients and identified the oxidative phosphorylation pathway as one of the significantly perturbed pathways. In addition, Lee and colleagues, <xref rid="ref-45" ref-type="bibr">(2015a)</xref> also showed that the expression of OxPhos gene sets was significantly lower in primary PTC than in matched normal thyroid tissue. Our findings revealed a similar trend with OxPhos genes being significantly downregulated in PTCs versus normal thyroid tissues as well as in PTC LNM-P versus PTC LNN. However, significant enrichment of OxPhos pathway was only observed in PTC LNM-P compared to PTC LNN. Alteration in metabolic processes has been considered as an indispensable component of malignant transformation (<xref rid="ref-45" ref-type="bibr">Lee et al.</xref>, <xref rid="ref-45" ref-type="bibr">2015a</xref>) thus the involvement of oxidative phosphorylation in LNM in PTC necessitates further investigation.</p><p>Oxidative phosphorylation is a process whereby an adenosine triphosphate (ATP) is produced as a result of electrons transfer from nicotinamide adenine dinucleotide (NADH) or flavin-adenine dinucleotide (FADH<sub>2</sub>) to oxygen by a series of electron carriers (<xref rid="ref-7" ref-type="bibr">Berg, Tymoczko &#x00026; Stryer</xref>, <xref rid="ref-7" ref-type="bibr">2002</xref>). The thyroid gland is an endocrine organ with a high energy consumption and oxidative processes are crucial for thyroid hormone synthesis (<xref rid="ref-42" ref-type="bibr">Lee et al.</xref>, <xref rid="ref-42" ref-type="bibr">2015b</xref>). The mitochondria is responsible for providing 90% of the cellular energy necessary for various biological functions through oxidative phosphorylation and plays an important role in energy metabolism in the normal thyroid gland and in thyroid tumors (<xref rid="ref-41" ref-type="bibr">Kim et al.</xref>, <xref rid="ref-41" ref-type="bibr">2012</xref>). The mitochondria is involved in many cell signaling pathways by playing crucial roles in apoptosis, cell proliferation and cellular Ca<sup>2+</sup> homeostasis (<xref rid="ref-60" ref-type="bibr">Rustin</xref>, <xref rid="ref-60" ref-type="bibr">2002</xref>). Mitochondrial DNA (mtDNA) content was shown to be higher in PTC compared to the paired normal DNA and in normal controls (<xref rid="ref-51" ref-type="bibr">Mambo et al.</xref>, <xref rid="ref-51" ref-type="bibr">2005</xref>). Despite advancement in the elucidation of molecular events underlying thyroid carcinogenesis in the last decade, the function and nature of energy metabolism in thyroid cancer remain unclear (<xref rid="ref-42" ref-type="bibr">Lee et al.</xref>, <xref rid="ref-42" ref-type="bibr">2015b</xref>).</p><p>In addition to oxidative phosphorylation, we also identified significant enrichment of other cancer-related pathways such as cell adhesion molecules (CAMs), leukocyte transendothelial migration and cytokine&#x02013;cytokine receptor interaction pathways which were unique to PTC LNM-P versus PTC LNN. Interestingly, these pathways were not significantly enriched when PTCs (LNM-P and LNN) were compared to normal thyroid tissues. Taken together, it could be hypothesized that metastasis to the lymph node in PTC occurred via changes in the aforementioned pathways. However, some pathways in our analysis, such as valine, leucine and isoleucine degradation, could not be associated with oncogenesis or metastasis and may need further investigation.</p><p>Our integrated analysis revealed hsa-miR-301b&#x02019;s presence in the top 20 circuits in both PTC LNM-P versus PTC LNN and PTC LNM-P versus normal thyroid but was absent in PTC LNN versus normal thyroid despite significant downregulation with modest fold change (log<sub>2</sub> fold change of &#x02212;0.3). Hsa-miR-301 is located in the intronic region of <italic>SKA2</italic> (spindle and kinetochore associated complex subunit 2) and belongs to the hsa-miR-130 microRNA precursor family (<xref rid="ref-12" ref-type="bibr">Cao et al.</xref>, <xref rid="ref-12" ref-type="bibr">2010</xref>). In contrast to our findings, hsa-miR-301 upregulation has been reported in various cancers of non-thyroid origins and given that a miRNA can act either as an oncomiR or tumor suppressor depending on the cellular context and tissue type (<xref rid="ref-24" ref-type="bibr">Garzon, Calin &#x00026; Croce</xref>, <xref rid="ref-24" ref-type="bibr">2009</xref>), this observation is not unexpected. There is no evidence of hsa-miR-301b dysregulation in PTC so far, but it was reported to be upregulated in follicular thyroid adenoma compared to normal thyroid tissue (<xref rid="ref-59" ref-type="bibr">Rossing et al.</xref>, <xref rid="ref-59" ref-type="bibr">2012</xref>). It is also upregulated in CRC without LNM in comparison to paracancerous control (<xref rid="ref-69" ref-type="bibr">Wang et al.</xref>, <xref rid="ref-69" ref-type="bibr">2010b</xref>). The inhibition of hsa-miR-301 decreased breast cancer cell proliferation, clonogenicity, migration, invasion, tamoxifen resistance, tumor growth and microvessel density, further establishing this miRNA as an oncomiR (<xref rid="ref-62" ref-type="bibr">Shi et al.</xref>, <xref rid="ref-62" ref-type="bibr">2011</xref>). <italic>FOXF2</italic>, <italic>BBC3</italic>, <italic>PTEN</italic>, and <italic>COL2A1</italic> were confirmed as its direct targets through luciferase reporter assays (<xref rid="ref-62" ref-type="bibr">Shi et al.</xref>, <xref rid="ref-62" ref-type="bibr">2011</xref>).</p><p>Transcription factors (TFs) are a group of proteins involved in the initiation of transcription and are important for the regulation of genes. Majority of oncogenes and tumor suppressor genes encode the TFs (<xref rid="ref-20" ref-type="bibr">Ell &#x00026; Kang, 2013</xref>). Dysregulation of oncogenic or tumor suppressive TFs could influence multiple steps of the metastasis cascade, leading to cancer progression (<xref rid="ref-20" ref-type="bibr">Ell &#x00026; Kang, 2013</xref>). The involvement of TFs in PTC has been investigated since decades ago and several thyroid-specific TFs have been identified (<xref rid="ref-28" ref-type="bibr">Guazzi et al.</xref>, <xref rid="ref-28" ref-type="bibr">1990</xref>; <xref rid="ref-21" ref-type="bibr">Fabbro et al.</xref>, <xref rid="ref-21" ref-type="bibr">1994</xref>). Most recently, the glioma-associated oncogene homolog 1 (GLI1) has been identified as a TF marker for LNM in PTC and it increases tumor aggressiveness via the Hedgehog signaling pathway (<xref rid="ref-43" ref-type="bibr">Lee et al.</xref>, <xref rid="ref-43" ref-type="bibr">2015c</xref>). The hepatic leukemia factor (HLF) is the only TF which appeared in the top 20 circuits of PTCs with or without LNM versus normal thyroid from our integrated analysis. On the other hand, REL was identified in the top 20 circuits only in PTC LNM-P in comparison to PTC LNN and will be discussed further in the following section.</p><p>The HLF is a transcription factor that facilitates thyroid hormone activation from the thyroid hormone receptor/retinoid X receptor heterodimer to hypoxia-inducible factor (HIF-1<italic>&#x003b1;</italic>) (<xref rid="ref-55" ref-type="bibr">Otto &#x00026; Fandrey</xref>, <xref rid="ref-55" ref-type="bibr">2008</xref>). Triiodothyronine (T3) indirectly increases HIF-1<italic>&#x003b1;</italic> mRNA by increasing the expression of HLF, subsequently initiating the transcription of HIF-1<italic>&#x003b1;</italic> transcription factor (<xref rid="ref-9" ref-type="bibr">Burrows et al.</xref>, <xref rid="ref-9" ref-type="bibr">2011</xref>). HIF is another transcription factor which acts under hypoxia and thus is active in a number of diseases associated with low oxygen environment including cancer (<xref rid="ref-9" ref-type="bibr">Burrows et al.</xref>, <xref rid="ref-9" ref-type="bibr">2011</xref>). In fact, the HIF-1<italic>&#x003b1;</italic> protein was differentially expressed in primary thyroid cancers associated with advanced stage; its expression was supressed in normal thyroid tissue and was highest in the most aggressive dedifferentiated anaplastic thyroid carcinomas (ATCs) (<xref rid="ref-29" ref-type="bibr">Hanada, Feng &#x00026; Hemmings</xref>, <xref rid="ref-29" ref-type="bibr">2004</xref>), supporting its role for thyroid tumor aggressiveness, progression as well as metastasis. In addition, we also identified a significant involvement of REL/NFkB in lymph node metastasis of PTC which is in concordance with previously published data (<xref rid="ref-19" ref-type="bibr">Du et al.</xref>, <xref rid="ref-19" ref-type="bibr">2006</xref>).</p><p>In summary, we found evidence of five miRNAs differentially expressed in PTC LNM-P. Enrichment analysis revealed that alteration in oxidative phosphorylation pathway could be a key event involved in the lymph node metastasis of PTC suggesting that manipulation of the energy metabolism processes may provide an alternative therapeutic target for tackling metastasis or recurrence. In addition, via the integrated analysis we discovered that hsa-miR-301b might be involved in promoting LNM in PTC via activation of HLF, HIF and REL/NFkB. As far as we know, the roles of these TFs have been explored in PTC; however the exact roles of this miRNA with these TFs in LNM in PTC have not been studied. Hence, further investigation is necessary for future research in order to completely unravel the mechanism of LNM in PTC.</p></sec><sec sec-type="supplementary-material" id="supplemental-information"><title> Supplemental Information</title><supplementary-material content-type="local-data" id="supp-1"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-1</object-id><label>Table S1</label><caption><title>TCGA sample IDs of 477 papillary thyroid cancer patients with microRNA and gene expression data</title></caption><media xlink:href="peerj-04-2119-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-2"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-2</object-id><label>Table S2</label><caption><title>181 significantly deregulated miRNAs with respective log<sub>2</sub> fold change and <italic>p</italic> value in PTC LNM-P versus PTC LNN</title></caption><media xlink:href="peerj-04-2119-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-3"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-3</object-id><label>Table S3</label><caption><title>78 significantly deregulated miRNAs with respective log<sub>2</sub> fold change and <italic>p</italic> value in PTCs (LNM-P and LNN) versus normal thyroid</title></caption><media xlink:href="peerj-04-2119-s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-4"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-4</object-id><label>File S1</label><caption><title>R script for miRNAseq differential analysis</title></caption><media xlink:href="peerj-04-2119-s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-5"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-5</object-id><label>Table S4</label><caption><title>407 significantly deregulated genes with respective log<sub>2</sub> fold change and <italic>p</italic> value in PTC LNM-P versus PTC LNN</title></caption><media xlink:href="peerj-04-2119-s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-6"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-6</object-id><label>File S2</label><caption><title>R script for mRNAseq differential analysis</title></caption><media xlink:href="peerj-04-2119-s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-7"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-7</object-id><label>Data S1</label><caption><title>Raw counts generated from miRNAseq in validation experiment</title></caption><media xlink:href="peerj-04-2119-s007.txt"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-8"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-8</object-id><label>Figure S1</label><caption><title>Heat Map of the 395 Differentially Expressed miRNAs in PTC LNM-P versus normal thyroid. (Student&#x02019;s T-test with BH corrected <italic>p</italic> value &#x02264;0.05)</title></caption><media xlink:href="peerj-04-2119-s008.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-9"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-9</object-id><label>Figure S2</label><caption><title>Heat Map of the 400 Differentially Expressed miRNAs in PTC LNN versus normal thyroid. (Student&#x02019;s T-test with BH corrected <italic>p</italic> value &#x02264;0.05)</title></caption><media xlink:href="peerj-04-2119-s009.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="supp-10"><object-id pub-id-type="doi">10.7717/peerj.2119/supp-10</object-id><label>Figure S3</label><caption><title>Top 20 mixed regulatory circuits, involving miRNAs, genes and TFs</title><p>There are two types of mixed regulatory circuits; a TF regulating both a given miRNA and its target gene and a miRNA that regulates both a given TF and its regulated gene. (A) PTC LNM-P compared to PTC LNN. (B) PTC LNM-P compared to normal thyroid. (C) PTC LNN compared to normal thyroid.</p></caption><media xlink:href="peerj-04-2119-s010.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec sec-type="additional-information"><title>Additional Information and Declarations</title><fn-group content-type="competing-interests"><title>Competing Interests</title><fn id="conflict-1" fn-type="conflict"><p>The authors declare that there are no competing interests.</p></fn></fn-group><fn-group content-type="author-contributions"><title>Author Contributions</title><fn id="contribution-1" fn-type="con"><p><xref ref-type="contrib" rid="author-1">Nurul-Syakima Ab Mutalib</xref> conceived and designed the experiments, performed the experiments, wrote the paper, prepared figures and/or tables.</p></fn><fn id="contribution-2" fn-type="con"><p><xref ref-type="contrib" rid="author-2">Sri Noraima Othman</xref> analyzed the data, contributed reagents/materials/analysis tools.</p></fn><fn id="contribution-3" fn-type="con"><p><xref ref-type="contrib" rid="author-3">Azliana Mohamad Yusof</xref> analyzed the data.</p></fn><fn id="contribution-4" fn-type="con"><p><xref ref-type="contrib" rid="author-4">Shahrun Niza Abdullah Suhaimi</xref>, <xref ref-type="contrib" rid="author-5">Rohaizak Muhammad</xref> and <xref ref-type="contrib" rid="author-6">Rahman Jamal</xref> wrote the paper, reviewed drafts of the paper.</p></fn></fn-group><fn-group content-type="other"><title>Human Ethics</title><fn id="addinfo-1"><p>The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):</p><p>Universiti Kebangsaan Malaysia Research Ethics Committee (UKMREC).</p></fn></fn-group><fn-group content-type="other"><title>Ethics</title><fn id="addinfo-2"><p>The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):</p><p>Universiti Kebangsaan Malaysia Research Ethics Committee (UKMREC) (reference: UKM 1.5.3.5/244/UMBI-2015-002).</p></fn></fn-group><fn-group content-type="other"><title>Data Availability</title><fn id="addinfo-3"><p>The following information was supplied regarding data availability:</p><p>The raw data generated from the validation study has been supplied as <xref ref-type="supplementary-material" rid="supp-7">Data S1</xref>.</p></fn></fn-group></sec><ref-list content-type="authoryear"><title>References</title><ref id="ref-1"><label>Acibucu et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acibucu</surname><given-names>F</given-names></name><name><surname>D&#x000f6;kmeta&#x0015f;</surname><given-names>HS</given-names></name><name><surname>Tutar</surname><given-names>Y</given-names></name><name><surname>Elagoz</surname><given-names>S</given-names></name><name><surname>Kilicli</surname><given-names>F</given-names></name></person-group><year>2014</year><article-title>Correlations between the expression levels of microRNA146b, 221, 222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers</article-title><source>Experimental and Clinical Endocrinology &#x00026;amp; Diabetes</source><volume>122</volume><issue>3</issue><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1367025</pub-id><pub-id pub-id-type="pmid">24643689</pub-id></element-citation></ref><ref id="ref-2"><label>AJCC (2010)</label><element-citation publication-type="book"><person-group><collab><institution>AJCC</institution></collab></person-group><person-group person-group-type="editor"><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Byrd</surname><given-names>DR</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name><name><surname>Fritz</surname><given-names>AG</given-names></name><name><surname>Greene</surname><given-names>FL</given-names></name><name><surname>Trotti</surname><given-names>A</given-names></name></person-group><article-title>Thyroid</article-title><source>AJCC cancer staging manual</source><year>2010</year><publisher-name>Springer</publisher-name><publisher-loc>New York</publisher-loc><edition>7th edition</edition><fpage>87</fpage><lpage>96</lpage></element-citation></ref><ref id="ref-3"><label>Alexiou et al. (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexiou</surname><given-names>P</given-names></name><name><surname>Maragkakis</surname><given-names>M</given-names></name><name><surname>Papadopoulos</surname><given-names>GL</given-names></name><name><surname>Reczko</surname><given-names>M</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name></person-group><year>2009</year><article-title>Lost in translation: an assessment and perspective for computational microRNA target identification</article-title><source>Bioinformatics</source><volume>25</volume><issue>23</issue><fpage>3049</fpage><lpage>3055</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp565</pub-id><pub-id pub-id-type="pmid">19789267</pub-id></element-citation></ref><ref id="ref-4"><label>Bao et al. (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>HH</given-names></name><name><surname>Tian</surname><given-names>FJ</given-names></name><name><surname>He</surname><given-names>XY</given-names></name><name><surname>Qiu</surname><given-names>MT</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>HJ</given-names></name><name><surname>Wang</surname><given-names>LH1</given-names></name><name><surname>Wan</surname><given-names>XP</given-names></name></person-group><year>2013</year><article-title>A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells</article-title><source>Molecular Cancer</source><volume>12</volume><comment>155</comment><pub-id pub-id-type="doi">10.1186/1476-4598-12-155</pub-id></element-citation></ref><ref id="ref-5"><label>Bartel (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><year>2009</year><article-title>Micrornas: target recognition and regulatory functions</article-title><source>Cell</source><volume>136</volume><issue>2</issue><fpage>215</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.002</pub-id><pub-id pub-id-type="pmid">19167326</pub-id></element-citation></ref><ref id="ref-6"><label>Beattie et al. (2006)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beattie</surname><given-names>J</given-names></name><name><surname>Allan</surname><given-names>GJ</given-names></name><name><surname>Lochrie</surname><given-names>JD</given-names></name><name><surname>Flint</surname><given-names>DJ</given-names></name></person-group><year>2006</year><article-title>Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis</article-title><source>Biochemical Journal</source><volume>395</volume><issue>1</issue><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1042/BJ20060086</pub-id><pub-id pub-id-type="pmid">16526944</pub-id></element-citation></ref><ref id="ref-7"><label>Berg, Tymoczko &#x00026; Stryer (2002)</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>JM</given-names></name><name><surname>Tymoczko</surname><given-names>JL</given-names></name><name><surname>Stryer</surname><given-names>L</given-names></name></person-group><year>2002</year><source>Biochemistry</source><publisher-name>WH Freeman</publisher-name><publisher-loc>New York</publisher-loc><edition>5th edition</edition></element-citation></ref><ref id="ref-8"><label>Bisognin et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisognin</surname><given-names>A</given-names></name><name><surname>Sales</surname><given-names>G</given-names></name><name><surname>Coppe</surname><given-names>A</given-names></name><name><surname>Bortoluzzi</surname><given-names>S</given-names></name><name><surname>Romualdi</surname><given-names>C</given-names></name></person-group><year>2012</year><article-title>MAGIA<sup>2</sup>: from miRNA and genes expression data integrative analysis to microRNA-transcription factor mixed regulatory circuits (2012 update)</article-title><source>Nucleic Acids Research</source><volume>40</volume><issue>Web Server issue</issue><fpage>W12</fpage><lpage>W21</lpage><pub-id pub-id-type="doi">10.1093/nar/gks460</pub-id></element-citation></ref><ref id="ref-9"><label>Burrows et al. (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burrows</surname><given-names>N</given-names></name><name><surname>Babur</surname><given-names>M</given-names></name><name><surname>Resch</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>KJ</given-names></name><name><surname>Brabant</surname><given-names>G</given-names></name></person-group><year>2011</year><article-title>Hypoxia-inducible factor in thyroid carcinoma</article-title><source>Journal of Thyroid Research</source><volume>2011</volume><fpage>762905</fpage><pub-id pub-id-type="doi">10.4061/2011/762905</pub-id><pub-id pub-id-type="pmid">21765994</pub-id></element-citation></ref><ref id="ref-10"><label>Cady &#x00026; Rosai (1988)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cady</surname><given-names>B</given-names></name><name><surname>Rosai</surname><given-names>R</given-names></name></person-group><year>1988</year><article-title>An expanded view of risk group definition in differentiated thyroid carcinoma</article-title><source>Surgery</source><volume>104</volume><issue>6</issue><fpage>947</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">3194846</pub-id></element-citation></ref><ref id="ref-11"><label>Cancer Genome Atlas Research Network (2014)</label><element-citation publication-type="journal"><year>2014</year><person-group><collab>Cancer Genome Atlas Research Network</collab></person-group><article-title>Integrated genomic characterization of papillary thyroid carcinoma</article-title><source>Cell</source><volume>159</volume><issue>3</issue><fpage>676</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.050</pub-id><pub-id pub-id-type="pmid">25417114</pub-id></element-citation></ref><ref id="ref-12"><label>Cao et al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Shao</surname><given-names>N</given-names></name></person-group><year>2010</year><article-title>Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways</article-title><source>Biochemical and Biophysical Research Communications</source><volume>396</volume><issue>4</issue><fpage>978</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.05.037</pub-id><pub-id pub-id-type="pmid">20470754</pub-id></element-citation></ref><ref id="ref-13"><label>Chen et al. (2008)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Kitabayashi</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>XK</given-names></name><name><surname>Fahey</surname><given-names>TJ</given-names><suffix>III</suffix></name><name><surname>Scognamiglio</surname><given-names>T</given-names></name></person-group><year>2008</year><article-title>MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma</article-title><source>Modern Pathology</source><volume>21</volume><issue>9</issue><fpage>1139</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2008.105</pub-id><pub-id pub-id-type="pmid">18587330</pub-id></element-citation></ref><ref id="ref-14"><label>Chou et al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>CK</given-names></name><name><surname>Chen</surname><given-names>RF</given-names></name><name><surname>Chou</surname><given-names>FF</given-names></name><name><surname>Chang</surname><given-names>HW</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>YF</given-names></name><name><surname>Yang</surname><given-names>KD</given-names></name><name><surname>Cheng</surname><given-names>JT</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Liu</surname><given-names>RT</given-names></name></person-group><year>2010</year><article-title>miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation</article-title><source>Thyroid</source><volume>20</volume><issue>5</issue><fpage>489</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1089/thy.2009.0027</pub-id><pub-id pub-id-type="pmid">20406109</pub-id></element-citation></ref><ref id="ref-15"><label>Chou et al. (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>CK</given-names></name><name><surname>Yang</surname><given-names>KD</given-names></name><name><surname>Chou</surname><given-names>FF</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Lan</surname><given-names>YW</given-names></name><name><surname>Lee</surname><given-names>YF</given-names></name><name><surname>Kang</surname><given-names>HY</given-names></name><name><surname>Liu</surname><given-names>RT</given-names></name></person-group><year>2013</year><article-title>Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma</article-title><source>Journal of Clinical Endocrinology and Metabolism</source><volume>98</volume><issue>2</issue><fpage>E196</fpage><lpage>E205</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-2666</pub-id><pub-id pub-id-type="pmid">23264400</pub-id></element-citation></ref><ref id="ref-16"><label>Cordero et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordero</surname><given-names>F</given-names></name><name><surname>Beccuti</surname><given-names>M</given-names></name><name><surname>Arigoni</surname><given-names>M</given-names></name><name><surname>Donatelli</surname><given-names>S</given-names></name><name><surname>Calogero</surname><given-names>RA</given-names></name></person-group><year>2012</year><article-title>Optimizing a massive parallel sequencing workflow for quantitative miRNA expression analysis</article-title><source>PLoS ONE</source><volume>7</volume><issue>2</issue><elocation-id>e2119</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0031630</pub-id></element-citation></ref><ref id="ref-17"><label>De Carvalho et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Carvalho</surname><given-names>AC</given-names></name><name><surname>Scapulatempo-Neto</surname><given-names>C</given-names></name><name><surname>Maia</surname><given-names>DC</given-names></name><name><surname>Evangelista</surname><given-names>AF</given-names></name><name><surname>Morini</surname><given-names>MA</given-names></name><name><surname>Carvalho</surname><given-names>AL</given-names></name><name><surname>Vettore</surname><given-names>AL</given-names></name></person-group><year>2015</year><article-title>Accuracy of microRNAs as markers for the detection of neck lymph node metastases in patients with head and neck squamous cell carcinoma</article-title><source>BMC Medicine</source><volume>13</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/s12916-015-0350-3</pub-id><pub-id pub-id-type="pmid">25956054</pub-id></element-citation></ref><ref id="ref-18"><label>Deng et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name></person-group><year>2015</year><article-title>MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3</article-title><source>Cellular Physiology and Biochemistry</source><volume>35</volume><issue>1</issue><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1159/000369676</pub-id><pub-id pub-id-type="pmid">25547151</pub-id></element-citation></ref><ref id="ref-19"><label>Du et al. (2006)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>ZX</given-names></name><name><surname>Zhang</surname><given-names>HY</given-names></name><name><surname>Gao</surname><given-names>DX</given-names></name><name><surname>Wang</surname><given-names>HQ</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Liu</surname><given-names>GL</given-names></name></person-group><year>2006</year><article-title>Significance of VEGF and NF-<italic>&#x003ba;</italic>B expression in thyroid carcinoma</article-title><source>Chinese Journal of Clinical Oncology</source><volume>3</volume><fpage>166</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1007/s11805-006-0112-2</pub-id></element-citation></ref><ref id="ref-20"><label>Ell &#x00026; Kang (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ell</surname><given-names>B</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name></person-group><year>2013</year><article-title>Transcriptional control of cancer metastasis</article-title><source>Trends in Cell Biology</source><volume>23</volume><issue>12</issue><fpage>603</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2013.06.001</pub-id><pub-id pub-id-type="pmid">23838335</pub-id></element-citation></ref><ref id="ref-21"><label>Fabbro et al. (1994)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Di Loreto</surname><given-names>C</given-names></name><name><surname>Beltrami</surname><given-names>CA</given-names></name><name><surname>Belfiore</surname><given-names>A</given-names></name><name><surname>Di Lauro</surname><given-names>R</given-names></name><name><surname>Damante</surname><given-names>G</given-names></name></person-group><year>1994</year><article-title>Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms</article-title><source>Cancer Research</source><volume>54</volume><issue>17</issue><fpage>4744</fpage><lpage>4749</lpage><pub-id pub-id-type="pmid">8062273</pub-id></element-citation></ref><ref id="ref-22"><label>Fassina et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fassina</surname><given-names>A</given-names></name><name><surname>Cappellesso</surname><given-names>R</given-names></name><name><surname>Simonato</surname><given-names>F</given-names></name><name><surname>Siri</surname><given-names>M</given-names></name><name><surname>Ventura</surname><given-names>L</given-names></name><name><surname>Tosato</surname><given-names>F</given-names></name><name><surname>Busund</surname><given-names>LT</given-names></name><name><surname>Pelizzo</surname><given-names>MR</given-names></name><name><surname>Fassan</surname><given-names>M</given-names></name></person-group><year>2014</year><article-title>A 4-MicroRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears</article-title><source>Cancer Cytopathology</source><volume>122</volume><issue>4</issue><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1002/cncy.21383</pub-id><pub-id pub-id-type="pmid">24327568</pub-id></element-citation></ref><ref id="ref-23"><label>Friard et al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friard</surname><given-names>O</given-names></name><name><surname>Re</surname><given-names>A</given-names></name><name><surname>Taverna</surname><given-names>D</given-names></name><name><surname>De Bortoli</surname><given-names>M</given-names></name><name><surname>Cor&#x000e1;</surname><given-names>D</given-names></name></person-group><year>2010</year><article-title>CircuitsDB: a database of mixed microRNA/transcription factor feed-forward regulatory circuits in human and mouse</article-title><source>BMC Bioinformatics</source><volume>11</volume><fpage>435</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-11-435</pub-id><pub-id pub-id-type="pmid">20731828</pub-id></element-citation></ref><ref id="ref-24"><label>Garzon, Calin &#x00026; Croce (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garzon</surname><given-names>R</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><year>2009</year><article-title>MicroRNAs in cancer</article-title><source>Annual Review of Medicine</source><volume>60</volume><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.59.053006.104707</pub-id></element-citation></ref><ref id="ref-25"><label>Gentleman et al. (2004)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentleman</surname><given-names>RC</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name><name><surname>Bates</surname><given-names>DM</given-names></name><name><surname>Bolstad</surname><given-names>B</given-names></name><name><surname>Dettling</surname><given-names>M</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name><name><surname>Ellis</surname><given-names>B</given-names></name><name><surname>Gautier</surname><given-names>L</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Hornik</surname><given-names>K</given-names></name><name><surname>Hothorn</surname><given-names>T</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Iacus</surname><given-names>S</given-names></name><name><surname>Irizarry</surname><given-names>R</given-names></name><name><surname>Leisch</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Maechler</surname><given-names>M</given-names></name><name><surname>Rossini</surname><given-names>AJ</given-names></name><name><surname>Sawitzki</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Smyth</surname><given-names>G</given-names></name><name><surname>Tierney</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year>2004</year><article-title>Bioconductor: open software development for computational biology and bioinformatics</article-title><source>Genome Biology</source><volume>5</volume><issue>10</issue><comment>R80</comment><pub-id pub-id-type="doi">10.1186/gb-2004-5-10-r80</pub-id></element-citation></ref><ref id="ref-26"><label>Geraldo, Yamashita &#x00026; Kimura (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geraldo</surname><given-names>MV</given-names></name><name><surname>Yamashita</surname><given-names>AS</given-names></name><name><surname>Kimura</surname><given-names>ET</given-names></name></person-group><year>2012</year><article-title>MicroRNA miR-146b-5p regulates signal transduction of TGF-<italic>&#x003b2;</italic> by repressing SMAD4 in thyroid cancer</article-title><source>Oncogene</source><volume>31</volume><issue>15</issue><fpage>1910</fpage><lpage>1922</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.381</pub-id><pub-id pub-id-type="pmid">21874046</pub-id></element-citation></ref><ref id="ref-27"><label>Gowrishankar et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowrishankar</surname><given-names>B</given-names></name><name><surname>Ibragimova</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Slifker</surname><given-names>MJ</given-names></name><name><surname>Devarajan</surname><given-names>K</given-names></name><name><surname>Al-Saleem</surname><given-names>T</given-names></name><name><surname>Uzzo</surname><given-names>RG</given-names></name><name><surname>Cairns</surname><given-names>P</given-names></name></person-group><year>2014</year><article-title>MicroRNA expression signatures of stage, grade, and progression in clear cell RCC</article-title><source>Cancer Biology &#x00026;amp; Therapy</source><volume>15</volume><issue>3</issue><fpage>329</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.4161/cbt.27314</pub-id><pub-id pub-id-type="pmid">24351440</pub-id></element-citation></ref><ref id="ref-28"><label>Guazzi et al. (1990)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guazzi</surname><given-names>S</given-names></name><name><surname>Price</surname><given-names>M</given-names></name><name><surname>De Felice</surname><given-names>M</given-names></name><name><surname>Damante</surname><given-names>G</given-names></name><name><surname>Mattei</surname><given-names>MG</given-names></name><name><surname>Di Lauro</surname><given-names>R</given-names></name></person-group><year>1990</year><article-title>Thyroid nuclear factor 1 (TTF-1) contains a homeodomain and displays a novel DNA binding specificity</article-title><source>The EMBO Journal</source><volume>9</volume><issue>11</issue><fpage>3631</fpage><lpage>3639</lpage><pub-id pub-id-type="pmid">1976511</pub-id></element-citation></ref><ref id="ref-29"><label>Hanada, Feng &#x00026; Hemmings (2004)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanada</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Hemmings</surname><given-names>BA</given-names></name></person-group><year>2004</year><article-title>Structure, regulation and function of PKB/AKT&#x02013;a major therapeutic target</article-title><source>Biochimica et Biophysica ACTA/General Subjects</source><volume>1697</volume><issue>1&#x02013;2</issue><fpage>3</fpage><lpage>16</lpage></element-citation></ref><ref id="ref-30"><label>Hao et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>HX</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Charlat</surname><given-names>O</given-names></name><name><surname>Oster</surname><given-names>E</given-names></name><name><surname>Avello</surname><given-names>M</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Mickanin</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Ruffner</surname><given-names>H</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zamponi</surname><given-names>R</given-names></name><name><surname>Bouwmeester</surname><given-names>T</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Kirschner</surname><given-names>MW</given-names></name><name><surname>Porter</surname><given-names>JA</given-names></name><name><surname>Serluca</surname><given-names>FC</given-names></name><name><surname>Cong</surname><given-names>F</given-names></name></person-group><year>2012</year><article-title>ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner</article-title><source>Nature</source><volume>485</volume><issue>7397</issue><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nature11019</pub-id><pub-id pub-id-type="pmid">22575959</pub-id></element-citation></ref><ref id="ref-31"><label>Hay et al. (1993)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>ID</given-names></name><name><surname>Bergstrahl</surname><given-names>EJ</given-names></name><name><surname>Goellner</surname><given-names>JR</given-names></name><name><surname>Ebersold</surname><given-names>JR</given-names></name><name><surname>Grant</surname><given-names>CS</given-names></name></person-group><year>1993</year><article-title>Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989</article-title><source>Surgery</source><volume>114</volume><issue>6</issue><fpage>1050</fpage><lpage>1057</lpage><comment>discussion 1057&#x02013;1058</comment><pub-id pub-id-type="pmid">8256208</pub-id></element-citation></ref><ref id="ref-32"><label>Hay et al. (1987)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>ID</given-names></name><name><surname>Grant</surname><given-names>CS</given-names></name><name><surname>Taylor</surname><given-names>WF</given-names></name><name><surname>MaConahey</surname><given-names>WM</given-names></name></person-group><year>1987</year><article-title>Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of survical outcome using a novel prognostic scoring system</article-title><source>Surgery</source><volume>102</volume><issue>6</issue><fpage>1088</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">3686348</pub-id></element-citation></ref><ref id="ref-33"><label>He et al. (2005)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>H</given-names></name><name><surname>Jazdzewski</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liyanarachchi</surname><given-names>S</given-names></name><name><surname>Nagy</surname><given-names>R</given-names></name><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Franssila</surname><given-names>K</given-names></name><name><surname>Suster</surname><given-names>S</given-names></name><name><surname>Kloos</surname><given-names>RT</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>De la Chapelle</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>The role of microRNA genes in papillary thyroid carcinoma</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>102</volume><issue>52</issue><fpage>19075</fpage><lpage>19080</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509603102</pub-id><pub-id pub-id-type="pmid">16365291</pub-id></element-citation></ref><ref id="ref-34"><label>Huang et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>KH</given-names></name><name><surname>Lan</surname><given-names>YT</given-names></name><name><surname>Fang</surname><given-names>WL</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Lo</surname><given-names>SS</given-names></name><name><surname>Li</surname><given-names>AF</given-names></name><name><surname>Chiou</surname><given-names>SH</given-names></name><name><surname>Wu</surname><given-names>CW</given-names></name><name><surname>Shyr</surname><given-names>YM</given-names></name></person-group><year>2015</year><article-title>The correlation between miRNA and lymph node metastasis in gastric cancer</article-title><source>BioMed Research International</source><volume>2015</volume><fpage>543163</fpage><pub-id pub-id-type="doi">10.1155/2015/543163</pub-id><pub-id pub-id-type="pmid">25688358</pub-id></element-citation></ref><ref id="ref-35"><label>Huang, Sherman &#x00026; Lempicki (2009a)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><year>2009a</year><article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title><source>Nucleic Acids Research</source><volume>37</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id><pub-id pub-id-type="pmid">19033363</pub-id></element-citation></ref><ref id="ref-36"><label>Huang, Sherman &#x00026; Lempicki (2009b)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><year>2009b</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nature Protocols</source><volume>4</volume><issue>1</issue><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="ref-37"><label>Iorio &#x00026; Croce (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>MV</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><year>2012</year><article-title>Microrna dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review</article-title><source>EMBO Molecular Medicine</source><volume>4</volume><issue>3</issue><fpage>143</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1002/emmm.201100209</pub-id><pub-id pub-id-type="pmid">22351564</pub-id></element-citation></ref><ref id="ref-38"><label>Ito et al. (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Tomoda</surname><given-names>C</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Kihara</surname><given-names>M</given-names></name><name><surname>Higashiyama</surname><given-names>T</given-names></name><name><surname>Uruno</surname><given-names>T</given-names></name><name><surname>Takamura</surname><given-names>Y</given-names></name><name><surname>Miya</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Matsuzuka</surname><given-names>F</given-names></name><name><surname>Miyauchi</surname><given-names>A</given-names></name></person-group><year>2009</year><article-title>Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastasis to the lateral compartment</article-title><source>Endocrine Journal</source><volume>56</volume><issue>6</issue><fpage>759</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K09E-025</pub-id><pub-id pub-id-type="pmid">19506324</pub-id></element-citation></ref><ref id="ref-39"><label>Kanehisa &#x00026; Goto (2000)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name></person-group><year>2000</year><article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes</article-title><source>Nucleic Acids Research</source><volume>28</volume><issue>1</issue><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmid">10592173</pub-id></element-citation></ref><ref id="ref-40"><label>Kanehisa et al. (2016)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Kawashima</surname><given-names>M</given-names></name><name><surname>Furumichi</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>M</given-names></name></person-group><year>2016</year><article-title>KEGG as a reference resource for gene and protein annotation</article-title><source>Nucleic Acids Research</source><volume>44</volume><issue>D1</issue><fpage>D457</fpage><lpage>D462</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1070</pub-id><pub-id pub-id-type="pmid">26476454</pub-id></element-citation></ref><ref id="ref-41"><label>Kim et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kwon</surname><given-names>MC</given-names></name><name><surname>Ryu</surname><given-names>MJ</given-names></name><name><surname>Chung</surname><given-names>HK</given-names></name><name><surname>Tadi</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Kweon</surname><given-names>GR</given-names></name><name><surname>Ryu</surname><given-names>SW</given-names></name><name><surname>Jo</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Hatakeyama</surname><given-names>H</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Yim</surname><given-names>YH</given-names></name><name><surname>Chung</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>YY</given-names></name><name><surname>Shong</surname><given-names>M</given-names></name></person-group><year>2012</year><article-title>CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane</article-title><source>Cell Metabolism</source><volume>16</volume><issue>2</issue><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.06.012</pub-id><pub-id pub-id-type="pmid">22819524</pub-id></element-citation></ref><ref id="ref-42"><label>Lee et al. (2015b)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Kang</surname><given-names>YE</given-names></name><name><surname>Yi</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Joung</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Shong</surname><given-names>M</given-names></name></person-group><year>2015b</year><article-title>Mitochondrial energy metabolism and thyroid cancers</article-title><source>Endocrinology Metabolism</source><volume>30</volume><issue>2</issue><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.3803/EnM.2015.30.2.117</pub-id><pub-id pub-id-type="pmid">26194071</pub-id></element-citation></ref><ref id="ref-43"><label>Lee et al. (2015c)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>CR</given-names></name><name><surname>Ku</surname><given-names>CR</given-names></name><name><surname>Kang</surname><given-names>SW</given-names></name><name><surname>Jeong</surname><given-names>JJ</given-names></name><name><surname>Nam</surname><given-names>KH</given-names></name><name><surname>Shin</surname><given-names>DY</given-names></name><name><surname>Chung</surname><given-names>WY</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Jo</surname><given-names>YS</given-names></name></person-group><year>2015c</year><article-title>GLI1 transcription factor affects tumor aggressiveness in patients with papillary thyroid cancers</article-title><source>Medicine</source><volume>94</volume><issue>25</issue><elocation-id>e2119</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000000998</pub-id><pub-id pub-id-type="pmid">26632732</pub-id></element-citation></ref><ref id="ref-44"><label>Lee et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>KR</given-names></name><name><surname>Cho</surname><given-names>NH</given-names></name><name><surname>Hong</surname><given-names>SR</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Kwon</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name><name><surname>An</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name><name><surname>Yoon</surname><given-names>HK</given-names></name><name><surname>Suh</surname><given-names>KS</given-names></name><name><surname>Min</surname><given-names>KO</given-names></name><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Yoo</surname><given-names>CW</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>WS</given-names></name><name><surname>Park</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name></person-group><year>2014</year><article-title>Gynecological pathology study group of the Korean society of pathologists. MicroRNA expression profiling and Notch1 and Notch2 expression in minimal deviation adenocarcinoma of uterine cervix</article-title><source>World Journal of Surgical Oncology</source><volume>12</volume><comment>334</comment><pub-id pub-id-type="doi">10.1186/1477-7819-12-334</pub-id></element-citation></ref><ref id="ref-45"><label>Lee et al. (2015a)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Seol</surname><given-names>MY</given-names></name><name><surname>Jeong</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>CR</given-names></name><name><surname>Ku</surname><given-names>CR</given-names></name><name><surname>Kang</surname><given-names>SW</given-names></name><name><surname>Jeong</surname><given-names>JJ</given-names></name><name><surname>Shin</surname><given-names>DY</given-names></name><name><surname>Nam</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Chung</surname><given-names>WY</given-names></name><name><surname>Jo</surname><given-names>YS</given-names></name></person-group><year>2015a</year><article-title>A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma</article-title><source>Medicine</source><volume>94</volume><issue>2</issue><elocation-id>e2119</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000000380</pub-id><pub-id pub-id-type="pmid">26632732</pub-id></element-citation></ref><ref id="ref-46"><label>Lee et al. (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Zhao</surname><given-names>JT</given-names></name><name><surname>Clifton-Bligh</surname><given-names>RJ</given-names></name><name><surname>Gill</surname><given-names>A</given-names></name><name><surname>Gundara</surname><given-names>JS</given-names></name><name><surname>Ip</surname><given-names>JC</given-names></name><name><surname>Glover</surname><given-names>A</given-names></name><name><surname>Sywak</surname><given-names>MS</given-names></name><name><surname>Delbridge</surname><given-names>LW</given-names></name><name><surname>Robinson</surname><given-names>BG</given-names></name><name><surname>Sidhu</surname><given-names>SB</given-names></name></person-group><year>2013</year><article-title>MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer</article-title><source>Cancer</source><volume>119</volume><issue>24</issue><fpage>4358</fpage><lpage>4365</lpage><pub-id pub-id-type="doi">10.1002/cncr.28254</pub-id><pub-id pub-id-type="pmid">24301304</pub-id></element-citation></ref><ref id="ref-47"><label>Li &#x00026; Dewey (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Dewey</surname><given-names>CN</given-names></name></person-group><year>2011</year><article-title>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</article-title><source>BMC Bioinformatics</source><volume>12</volume><fpage>323</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-12-323</pub-id><pub-id pub-id-type="pmid">21816040</pub-id></element-citation></ref><ref id="ref-48"><label>Li et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group><year>2014</year><article-title>Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer</article-title><source>International Journal of Clinical and Experimental Pathology</source><volume>7</volume><issue>6</issue><fpage>3287</fpage><lpage>3292</lpage><comment>eCollection 2014</comment><pub-id pub-id-type="pmid">25031750</pub-id></element-citation></ref><ref id="ref-49"><label>Liu et al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Xi</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name></person-group><year>2015</year><article-title>MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma</article-title><source>Biochemical and Biophysical Research Communications</source><volume>457</volume><issue>4</issue><fpage>621</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.01.037</pub-id><pub-id pub-id-type="pmid">25603050</pub-id></element-citation></ref><ref id="ref-50"><label>Ma et al. (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><year>2011</year><article-title>An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers</article-title><source>PLoS ONE</source><volume>6</volume><issue>10</issue><elocation-id>e2119</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0026502</pub-id></element-citation></ref><ref id="ref-51"><label>Mambo et al. (2005)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mambo</surname><given-names>E</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Xing</surname><given-names>M</given-names></name><name><surname>Tallini</surname><given-names>G</given-names></name><name><surname>Haugen</surname><given-names>BR</given-names></name><name><surname>Yeung</surname><given-names>SC</given-names></name><name><surname>Sukumar</surname><given-names>S</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name></person-group><year>2005</year><article-title>Tumor-specific changes in mtDNA content in human cancer</article-title><source>International Journal of Cancer</source><volume>116</volume><issue>6</issue><fpage>920</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1002/ijc.21110</pub-id><pub-id pub-id-type="pmid">15856456</pub-id></element-citation></ref><ref id="ref-52"><label>Maragkakis et al. (2009)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maragkakis</surname><given-names>M</given-names></name><name><surname>Reczko</surname><given-names>M</given-names></name><name><surname>Simossis</surname><given-names>VA</given-names></name><name><surname>Alexiou</surname><given-names>P</given-names></name><name><surname>Papadopoulos</surname><given-names>GL</given-names></name><name><surname>Dalamagas</surname><given-names>T</given-names></name><name><surname>Giannopoulos</surname><given-names>G</given-names></name><name><surname>Goumas</surname><given-names>G</given-names></name><name><surname>Koukis</surname><given-names>E</given-names></name><name><surname>Kourtis</surname><given-names>K</given-names></name><name><surname>Vergoulis</surname><given-names>T</given-names></name><name><surname>Koziris</surname><given-names>N</given-names></name><name><surname>Sellis</surname><given-names>T</given-names></name><name><surname>Tsanakas</surname><given-names>P</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name></person-group><year>2009</year><article-title>DIANA-microT web server: elucidating microRNA functions through target prediction</article-title><source>Nucleic Acids Research</source><volume>37</volume><issue>Web Server issue</issue><fpage>W273</fpage><lpage>W276</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp292</pub-id><pub-id pub-id-type="pmid">19406924</pub-id></element-citation></ref><ref id="ref-53"><label>Nilubol et al. (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilubol</surname><given-names>N</given-names></name><name><surname>Sukchotrat</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Kebebew</surname><given-names>E</given-names></name></person-group><year>2011</year><article-title>Molecular pathways associated with mortality in papillary thyroid cancer</article-title><source>Surgery</source><volume>150</volume><issue>6</issue><fpage>1023</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2011.09.021</pub-id><pub-id pub-id-type="pmid">22136817</pub-id></element-citation></ref><ref id="ref-54"><label>Nunez-Iglesias et al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunez-Iglesias</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Morgan</surname><given-names>TE</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>Zhou</surname><given-names>XJ</given-names></name></person-group><year>2010</year><article-title>Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer&#x02019;s disease cortex reveals altered miRNA regulation</article-title><source>PLoS ONE</source><volume>5</volume><issue>2</issue><elocation-id>e2119</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0008898</pub-id></element-citation></ref><ref id="ref-55"><label>Otto &#x00026; Fandrey (2008)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>T</given-names></name><name><surname>Fandrey</surname><given-names>J</given-names></name></person-group><year>2008</year><article-title>Thyroid hormone induces hypoxia-inducible factor 1alpha gene expression through thyroid hormone receptor beta/retinoid x receptor alpha-dependent activation of hepatic leukemia factor</article-title><source>Endocrinology</source><volume>149</volume><issue>5</issue><fpage>2241</fpage><lpage>2250</lpage><pub-id pub-id-type="doi">10.1210/en.2007-1238</pub-id><pub-id pub-id-type="pmid">18239067</pub-id></element-citation></ref><ref id="ref-56"><label>Pallante et al. (2006)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallante</surname><given-names>P</given-names></name><name><surname>Visone</surname><given-names>R</given-names></name><name><surname>Ferracin</surname><given-names>M</given-names></name><name><surname>Ferraro</surname><given-names>A</given-names></name><name><surname>Berlingieri</surname><given-names>MT</given-names></name><name><surname>Troncone</surname><given-names>G</given-names></name><name><surname>Chiappetta</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Negrini</surname><given-names>M</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>Fusco</surname><given-names>A</given-names></name></person-group><year>2006</year><article-title>MicroRNA deregulation in human thyroid papillary carcinomas</article-title><source>Endocrine-Related Cancer</source><volume>13</volume><issue>2</issue><fpage>497</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1677/erc.1.01209</pub-id><pub-id pub-id-type="pmid">16728577</pub-id></element-citation></ref><ref id="ref-57"><label>Pizzini et al. (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzini</surname><given-names>S</given-names></name><name><surname>Bisognin</surname><given-names>A</given-names></name><name><surname>Mandruzzato</surname><given-names>S</given-names></name><name><surname>Biasiolo</surname><given-names>M</given-names></name><name><surname>Facciolli</surname><given-names>A</given-names></name><name><surname>Perilli</surname><given-names>L</given-names></name><name><surname>Rossi</surname><given-names>E</given-names></name><name><surname>Esposito</surname><given-names>G</given-names></name><name><surname>Rugge</surname><given-names>M</given-names></name><name><surname>Pilati</surname><given-names>P</given-names></name><name><surname>Mocellin</surname><given-names>S</given-names></name><name><surname>Nitti</surname><given-names>D</given-names></name><name><surname>Bortoluzzi</surname><given-names>S</given-names></name><name><surname>Zanovello</surname><given-names>P</given-names></name></person-group><year>2013</year><article-title>Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis</article-title><source>BMC Genomics</source><volume>14</volume><fpage>589</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-14-589</pub-id><pub-id pub-id-type="pmid">23987127</pub-id></element-citation></ref><ref id="ref-58"><label>R Development Core Team (2008)</label><element-citation publication-type="book"><person-group><collab>R Development Core Team</collab></person-group><year>2008</year><source>R: a language and environment for statistical computing</source><publisher-loc>Vienna</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><comment><italic>Available at <ext-link ext-link-type="uri" xlink:href="https://www.R-project.org">https://www.R-project.org</ext-link></italic></comment><pub-id pub-id-type="other">ISBN 3-900051-07-0</pub-id></element-citation></ref><ref id="ref-59"><label>Rossing et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossing</surname><given-names>M</given-names></name><name><surname>Borup</surname><given-names>R</given-names></name><name><surname>Henao</surname><given-names>R</given-names></name><name><surname>Winther</surname><given-names>O</given-names></name><name><surname>Vikesaa</surname><given-names>J</given-names></name><name><surname>Niazi</surname><given-names>O</given-names></name><name><surname>Godballe</surname><given-names>C</given-names></name><name><surname>Krogdahl</surname><given-names>A</given-names></name><name><surname>Glud</surname><given-names>M</given-names></name><name><surname>Hjort-S&#x000f8;rensen</surname><given-names>C</given-names></name><name><surname>Kiss</surname><given-names>K</given-names></name><name><surname>Bennedb&#x000e6;k</surname><given-names>FN</given-names></name><name><surname>Nielsen</surname><given-names>FC</given-names></name></person-group><year>2012</year><article-title>Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma</article-title><source>Journal of Molecular Endocrinology</source><volume>48</volume><issue>1</issue><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1530/JME-11-0039</pub-id><pub-id pub-id-type="pmid">22049245</pub-id></element-citation></ref><ref id="ref-60"><label>Rustin (2002)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustin</surname><given-names>P</given-names></name></person-group><year>2002</year><article-title>Mitochondria, from cell death to proliferation</article-title><source>Nature Genetics</source><volume>30</volume><issue>4</issue><fpage>352</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1038/ng0402-352</pub-id><pub-id pub-id-type="pmid">11925557</pub-id></element-citation></ref><ref id="ref-61"><label>Schvartz et al. (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schvartz</surname><given-names>C</given-names></name><name><surname>Bonnetain</surname><given-names>F</given-names></name><name><surname>Dabakuyo</surname><given-names>S</given-names></name><name><surname>Gauthier</surname><given-names>M</given-names></name><name><surname>Cueff</surname><given-names>A</given-names></name><name><surname>Fieff&#x000e9;</surname><given-names>S</given-names></name><name><surname>Pochart</surname><given-names>JM</given-names></name><name><surname>Cochet</surname><given-names>I</given-names></name><name><surname>Crevisy</surname><given-names>E</given-names></name><name><surname>Dalac</surname><given-names>A</given-names></name><name><surname>Papathanassiou</surname><given-names>D</given-names></name><name><surname>Toubeau</surname><given-names>M</given-names></name></person-group><year>2012</year><article-title>Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients</article-title><source>Journal of Clinical Endocrinology and Metabolism</source><volume>97</volume><issue>5</issue><fpage>1526</fpage><lpage>1535</lpage><pub-id pub-id-type="doi">10.1210/jc.2011-2512</pub-id><pub-id pub-id-type="pmid">22344193</pub-id></element-citation></ref><ref id="ref-62"><label>Shi et al. (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Gerster</surname><given-names>K</given-names></name><name><surname>Alajez</surname><given-names>NM</given-names></name><name><surname>Tsang</surname><given-names>J</given-names></name><name><surname>Waldron</surname><given-names>L</given-names></name><name><surname>Pintilie</surname><given-names>M</given-names></name><name><surname>Hui</surname><given-names>AB</given-names></name><name><surname>Sykes</surname><given-names>J</given-names></name><name><surname>P'ng</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>N</given-names></name><name><surname>McCready</surname><given-names>D</given-names></name><name><surname>Fyles</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>FF</given-names></name></person-group><year>2011</year><article-title>MicroRNA-301 mediates proliferation and invasion in human breast cancer</article-title><source>Cancer Research</source><volume>71</volume><issue>8</issue><fpage>2926</fpage><lpage>2937</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3369</pub-id><pub-id pub-id-type="pmid">21393507</pub-id></element-citation></ref><ref id="ref-63"><label>Slaby et al. (2007)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slaby</surname><given-names>O</given-names></name><name><surname>Svoboda</surname><given-names>M</given-names></name><name><surname>Fabian</surname><given-names>P</given-names></name><name><surname>Smerdova</surname><given-names>T</given-names></name><name><surname>Knoflickova</surname><given-names>D</given-names></name><name><surname>Bednarikova</surname><given-names>M</given-names></name><name><surname>Nenutil</surname><given-names>R</given-names></name><name><surname>Vyzula</surname><given-names>R</given-names></name></person-group><year>2007</year><article-title>Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer</article-title><source>Oncology</source><volume>72</volume><issue>5--6</issue><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1159/000113489</pub-id><pub-id pub-id-type="pmid">18196926</pub-id></element-citation></ref><ref id="ref-64"><label>Sobin &#x00026; Wittekind (2002)</label><element-citation publication-type="book"><year>2002</year><person-group person-group-type="editor"><name><surname>Sobin</surname><given-names>LH</given-names></name><name><surname>Wittekind</surname><given-names>Ch</given-names></name></person-group><source>UICC: TNM classification of malignant tumors</source><publisher-name>WileyLiss</publisher-name><publisher-loc>New York</publisher-loc><edition>6th edition</edition></element-citation></ref><ref id="ref-65"><label>Sun et al. (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name></person-group><year>2013</year><article-title>Expression of miRNAs in papillary thyroid carcinomas is associated with BRAF mutation and clinicopathological features in Chinese patients</article-title><source>International Journal of Endocrinology</source><volume>2013</volume><fpage>128735</fpage><pub-id pub-id-type="doi">10.1155/2013/128735</pub-id><pub-id pub-id-type="pmid">23690767</pub-id></element-citation></ref><ref id="ref-66"><label>Swierniak et al. (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swierniak</surname><given-names>M</given-names></name><name><surname>Wojcicka</surname><given-names>A</given-names></name><name><surname>Czetwertynska</surname><given-names>M</given-names></name><name><surname>Stachlewska</surname><given-names>E</given-names></name><name><surname>Maciag</surname><given-names>M</given-names></name><name><surname>Wiechno</surname><given-names>W</given-names></name><name><surname>Gornicka</surname><given-names>B</given-names></name><name><surname>Bogdanska</surname><given-names>M</given-names></name><name><surname>Koperski</surname><given-names>L</given-names></name><name><surname>De la Chapelle</surname><given-names>A</given-names></name><name><surname>Jazdzewski</surname><given-names>K</given-names></name></person-group><year>2013</year><article-title>In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma</article-title><source>Journal of Clinical Endocrinology and Metabolism</source><volume>98</volume><issue>8</issue><fpage>E1401</fpage><lpage>E1409</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-1214</pub-id><pub-id pub-id-type="pmid">23783103</pub-id></element-citation></ref><ref id="ref-67"><label>Tetzlaff et al. (2007)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetzlaff</surname><given-names>MT</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Master</surname><given-names>SR</given-names></name><name><surname>Baldwin</surname><given-names>DA</given-names></name><name><surname>Tobias</surname><given-names>JW</given-names></name><name><surname>Livolsi</surname><given-names>VA</given-names></name><name><surname>Baloch</surname><given-names>ZW</given-names></name></person-group><year>2007</year><article-title>Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues</article-title><source>Endocrine Pathology</source><volume>18</volume><issue>3</issue><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1007/s12022-007-0023-7</pub-id><pub-id pub-id-type="pmid">18058265</pub-id></element-citation></ref><ref id="ref-68"><label>Wang et al. (2010a)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Cui</surname><given-names>Q</given-names></name></person-group><year>2010a</year><article-title>TransmiR: a transcription factor--microRNA regulation database</article-title><source>Nucleic Acids Research</source><volume>38</volume><fpage>D119</fpage><lpage>D122</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp803</pub-id><pub-id pub-id-type="pmid">19786497</pub-id></element-citation></ref><ref id="ref-69"><label>Wang et al. (2010b)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YX</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>BF</given-names></name><name><surname>Yang</surname><given-names>CQ</given-names></name><name><surname>Chen</surname><given-names>XM</given-names></name><name><surname>Gao</surname><given-names>HJ</given-names></name></person-group><year>2010b</year><article-title>Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis</article-title><source>Journal of Digestive Diseases</source><volume>11</volume><issue>1</issue><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1111/j.1751-2980.2009.00413.x</pub-id><pub-id pub-id-type="pmid">20132431</pub-id></element-citation></ref><ref id="ref-70"><label>Wojtas et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojtas</surname><given-names>B</given-names></name><name><surname>Ferraz</surname><given-names>C</given-names></name><name><surname>Stokowy</surname><given-names>T</given-names></name><name><surname>Hauptmann</surname><given-names>S</given-names></name><name><surname>Lange</surname><given-names>D</given-names></name><name><surname>Dralle</surname><given-names>H</given-names></name><name><surname>Musholt</surname><given-names>T</given-names></name><name><surname>Jarzab</surname><given-names>B</given-names></name><name><surname>Paschke</surname><given-names>R</given-names></name><name><surname>Eszlinger</surname><given-names>M</given-names></name></person-group><year>2014</year><article-title>Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas</article-title><source>Molecular and Cellular Endocrinology</source><volume>388</volume><issue>1--2</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2014.02.011</pub-id><pub-id pub-id-type="pmid">24631480</pub-id></element-citation></ref><ref id="ref-71"><label>Yan et al. (2008)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>LX</given-names></name><name><surname>Huang</surname><given-names>XF</given-names></name><name><surname>Shao</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>MY</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>QL</given-names></name><name><surname>Zeng</surname><given-names>YX</given-names></name><name><surname>Shao</surname><given-names>JY</given-names></name></person-group><year>2008</year><article-title>MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis</article-title><source>RNA</source><volume>14</volume><issue>11</issue><fpage>2348</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1261/rna.1034808</pub-id><pub-id pub-id-type="pmid">18812439</pub-id></element-citation></ref><ref id="ref-72"><label>Yang et al. (2013)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name></person-group><year>2013</year><article-title>Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma</article-title><source>Molecular Medicine Reports</source><volume>8</volume><issue>5</issue><fpage>1353</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.3892/mmr.2013.1699</pub-id><pub-id pub-id-type="pmid">24064622</pub-id></element-citation></ref><ref id="ref-73"><label>Yin et al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Fei</surname><given-names>B</given-names></name><name><surname>Quan</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Bian</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group><year>2014</year><article-title>miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22a</article-title><source>Clinical Cancer Research</source><volume>20</volume><issue>23</issue><fpage>6187</fpage><lpage>6199</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1030</pub-id><pub-id pub-id-type="pmid">25294901</pub-id></element-citation></ref><ref id="ref-74"><label>Yip et al. (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>L</given-names></name><name><surname>Shuai</surname><given-names>Y</given-names></name><name><surname>Armstrong</surname><given-names>MJ</given-names></name><name><surname>Nikiforov</surname><given-names>YE</given-names></name><name><surname>Carty</surname><given-names>SE</given-names></name><name><surname>Nikiforova</surname><given-names>MN</given-names></name></person-group><year>2011</year><article-title>MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma</article-title><source>Annals of Surgical Oncology</source><volume>18</volume><issue>7</issue><fpage>2035</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1245/s10434-011-1733-0</pub-id><pub-id pub-id-type="pmid">21537871</pub-id></element-citation></ref></ref-list></back></article>